



**PB 79 of 2023**

# **National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2023 (No. 8)**

*National Health Act 1953*

---

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the *National Health Act 1953*.

Dated                      30 August 2023

**NIKOLAI TSYGANOV**

Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division

---

---

## Contents

|                                                                                                  |                    |          |
|--------------------------------------------------------------------------------------------------|--------------------|----------|
| 1                                                                                                | Name .....         | 1        |
| 2                                                                                                | Commencement ..... | 1        |
| 3                                                                                                | Authority.....     | 1        |
| 4                                                                                                | Schedules .....    | 1        |
| <b>Schedule 1—Amendments</b>                                                                     |                    | <b>2</b> |
| <i>National Health (Listing of Pharmaceutical Benefits) Instrument 2012<br/>(PB 71 of 2012).</i> |                    | <i>2</i> |

---

## 1 Name

- (1) This instrument is the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2023 (No. 8)*.
- (2) This Instrument may also be cited as PB 79 of 2023.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information               |                                                                                                                                                                                                       |              |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Column 1                               | Column 2                                                                                                                                                                                              | Column 3     |
| Provisions                             | Commencement                                                                                                                                                                                          | Date/Details |
| 1. <i>The whole of this instrument</i> | Immediately after the commencement of Schedule 2 of the <i>National Health Legislation Amendment (Opioid Dependence Treatment and Maximum Dispensed Quantities) Instrument 2023 (PB 57 of 2023)</i> . |              |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## Schedule 1—Amendments

### ***National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)***

- [1] **Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 1; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances":* **C14133**
  - (b) *insert in numerical order in the column headed "Circumstances":* **C14275**
- [2] **Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 1; Number of Repeats: 3]**
- (a) *omit from the column headed "Circumstances" (all instances):* **C14133**
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14275**
- [3] **Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 2; Number of Repeats: 3]**
- (a) *omit from the column headed "Circumstances" (all instances):* **C14133**
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14275**
  - (c) *omit from the column headed "Purposes" (all instances):* **P14133**      *substitute (all instances):* **P14275**
- [4] **Schedule 1, Part 1, entry for Alendronic acid in the form Tablet 70 mg (as alendronate sodium) [Maximum Quantity: 4; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances):* **C14027 C14028 C14089**
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14242 C14291 C14309**
- [5] **Schedule 1, Part 1, entry for Alendronic acid in the form Tablet 70 mg (as alendronate sodium) [Maximum Quantity: 8; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances):* **C14027 C14028 C14089**
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14242 C14291 C14309**
  - (c) *omit from the column headed "Purposes" (all instances):* **P14027 P14028 P14089**      *substitute (all instances):* **P14242 P14291 P14309**

- 
- [6] **Schedule 1, Part 1, entry for Allopurinol in the form Tablet 100 mg [Maximum Quantity: 400; Number of Repeats: 2]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [7] **Schedule 1, Part 1, entry for Allopurinol in the form Tablet 300 mg [Maximum Quantity: 120; Number of Repeats: 2]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [8] **Schedule 1, Part 1, entry for Amlodipine in the form Tablet 5 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [9] **Schedule 1, Part 1, entry for Amlodipine in the form Tablet 10 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [10] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes": P14141* *substitute: P14238*
- [11] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes": P14141* *substitute: P14238*
- [12] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [13] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [14] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
-

- [15] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141*      *substitute (all instances): P14238*

- [16] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141*      *substitute (all instances): P14238*

- [17] **Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)**

*omit:*

|   |                |    |       |        |    |   |    |
|---|----------------|----|-------|--------|----|---|----|
| a | Cadivast 10/80 | AF | MP NP | P14141 | 60 | 5 | 30 |
| a | Caduet 10/80   | AS | MP NP | P14141 | 60 | 5 | 30 |

- [18] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-80 mg [Maximum Quantity: 28; Number of Repeats: 5]**

(a) *omit from the column headed "Circumstances" (all instances): C14043*

(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*

- [19] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-80 mg [Maximum Quantity: 56; Number of Repeats: 5]**

(a) *omit from the column headed "Circumstances" (all instances): C14043*

(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*

(c) *omit from the column headed "Purposes" (all instances): P14043*      *substitute (all instances): P14257*

- [20] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-160 mg [Maximum Quantity: 28; Number of Repeats: 5]**

(a) *omit from the column headed "Circumstances" (all instances): C14043*

(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*

- 
- [21] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-160 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
  - (c) *omit from the column headed "Purposes" (all instances): P14043*      *substitute (all instances): P14257*
- [22] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-320 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- [23] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-320 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
  - (c) *omit from the column headed "Purposes" (all instances): P14043*      *substitute (all instances): P14257*
- [24] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-160 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- [25] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-160 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
  - (c) *omit from the column headed "Purposes" (all instances): P14043*      *substitute (all instances): P14257*
- [26] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-320 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
-

- 
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- [27] **Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-320 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- (c) *omit from the column headed "Purposes" (all instances): P14043* *substitute (all instances): P14257*
- [28] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- [29] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- (c) *omit from the column headed "Purposes" (all instances): P14062* *substitute (all instances): P14272*
- [30] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- [31] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- (c) *omit from the column headed "Purposes" (all instances): P14062* *substitute (all instances): P14272*
-

- 
- [32] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-12.5 mg**  
**[Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- [33] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-12.5 mg**  
**[Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
  - (c) *omit from the column headed "Purposes" (all instances): P14062*      *substitute (all instances): P14272*
- [34] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-25 mg**  
**[Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- [35] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-25 mg**  
**[Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
  - (c) *omit from the column headed "Purposes" (all instances): P14062*      *substitute (all instances): P14272*
- [36] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-320 mg-25 mg**  
**[Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- [37] **Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-320 mg-25 mg**  
**[Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
-

- 
- (c) omit from the column headed "Purposes" (all instances): **P14062** substitute (all instances): **P14272**
- [38] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 20; Number of Repeats: 0]**  
(a) omit from the column headed "Circumstances": **C14078 C14139**  
(b) insert in numerical order in the column headed "Circumstances": **C14300 C14308**
- [39] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 30; Number of Repeats: 0]**  
(a) omit from the column headed "Circumstances": **C14078 C14139**  
(b) insert in numerical order in the column headed "Circumstances": **C14300 C14308**
- [40] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 0]**  
(a) omit from the column headed "Circumstances": **C14078 C14139**  
(b) insert in numerical order in the column headed "Circumstances": **C14300 C14308**
- [41] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) omit from the column headed "Circumstances": **C14078 C14139**  
(b) insert in numerical order in the column headed "Circumstances": **C14300 C14308**
- [42] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 120; Number of Repeats: 5]**  
(a) omit from the column headed "Circumstances": **C14078 C14139**  
(b) insert in numerical order in the column headed "Circumstances": **C14300 C14308**  
(c) omit from the column headed "Purposes": **P14078 P14139** substitute: **P14300 P14308**
- [43] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 28; Number of Repeats: 0]**  
(a) omit from the column headed "Circumstances": **C14078 C14095 C14129**  
(b) insert in numerical order in the column headed "Circumstances": **C14264 C14302 C14308**
- [44] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) omit from the column headed "Circumstances": **C14078 C14095 C14129**  
(b) insert in numerical order in the column headed "Circumstances": **C14264 C14302 C14308**
-

- [45] **Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 120; Number of Repeats: 5]**  
 (a) omit from the column headed "Circumstances": **C14078 C14095 C14129**  
 (b) insert in numerical order in the column headed "Circumstances": **C14264 C14302 C14308**  
 (c) omit from the column headed "Purposes": **P14078 P14095 P14129** substitute: **P14264 P14302 P14308**
- [46] **Schedule 1, Part 1, entry for Atenolol in the form Oral solution 50 mg in 10 mL, 300 mL [Maximum Quantity: 1; Number of Repeats: 5]**  
 (a) omit from the column headed "Circumstances": **C14039**  
 (b) insert in numerical order in the column headed "Circumstances": **C14305**
- [47] **Schedule 1, Part 1, entry for Atenolol in the form Oral solution 50 mg in 10 mL, 300 mL [Maximum Quantity: 2; Number of Repeats: 5]**  
 (a) omit from the column headed "Circumstances": **C14039**  
 (b) insert in numerical order in the column headed "Circumstances": **C14305**  
 (c) omit from the column headed "Purposes": **P14039** substitute: **P14305**
- [48] **Schedule 1, Part 1, entry for Atenolol in the form Tablet 50 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
 omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**
- [49] **Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 10 mg (as calcium)**  
 omit:

|   |                                    |    |    |       |    |    |    |
|---|------------------------------------|----|----|-------|----|----|----|
| a | APO-Atorvastatin                   | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol                         | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH                    | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ                    | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist<br>Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor                            | AS | MP | P7598 | 30 | 11 | 30 |
| a | Lorstat 10                         | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED<br>ATORVASTATIN             | VO | MP | P7598 | 30 | 11 | 30 |

|   |                           |    |    |       |    |    |    |
|---|---------------------------|----|----|-------|----|----|----|
| a | Pharmacor<br>Atorvastatin | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas                    | RA | MP | P7598 | 30 | 11 | 30 |

**[50] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 10 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[51] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium)**

*omit:*

|   |                                    |    |    |       |    |    |    |
|---|------------------------------------|----|----|-------|----|----|----|
| a | APO-Atorvastatin                   | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol                         | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH                    | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ                    | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist<br>Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor                            | AS | MP | P7598 | 30 | 11 | 30 |
| a | Lorstat 20                         | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED<br>ATORVASTATIN             | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor<br>Atorvastatin          | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas                             | RA | MP | P7598 | 30 | 11 | 30 |

**[52] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[53] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 40 mg (as calcium)**

*omit:*

|   |                                    |    |    |       |    |    |    |
|---|------------------------------------|----|----|-------|----|----|----|
| a | APO-Atorvastatin                   | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol                         | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH                    | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ                    | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist<br>Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor                            | AS | MP | P7598 | 30 | 11 | 30 |
| a | Lorstat 40                         | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED<br>ATORVASTATIN             | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor<br>Atorvastatin          | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas                             | RA | MP | P7598 | 30 | 11 | 30 |

**[54] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 40 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[55] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium)**

*omit:*

|   |                                    |    |    |       |    |    |    |
|---|------------------------------------|----|----|-------|----|----|----|
| a | APO-Atorvastatin                   | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol                         | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH                    | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ                    | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist<br>Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor                            | AS | MP | P7598 | 30 | 11 | 30 |

|   |                           |    |    |       |    |    |    |
|---|---------------------------|----|----|-------|----|----|----|
| a | Lorstat 80                | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED<br>ATORVASTATIN    | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor<br>Atorvastatin | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas                    | RA | MP | P7598 | 30 | 11 | 30 |

- [56] **Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**
- [57] **Schedule 1, Part 1, entry for Baclofen in the form Tablet 10 mg [Maximum Quantity: 200; Number of Repeats: 5]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**
- [58] **Schedule 1, Part 1, entry for Baclofen in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 5]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**
- [59] **Schedule 1, Part 1, entry for Balsalazide in the form Capsule containing balsalazide sodium 750 mg [Maximum Quantity: 280; Number of Repeats: 5]**  
(a) omit from the column headed "Circumstances": **C14084**  
(b) insert in numerical order in the column headed "Circumstances": **C14306**
- [60] **Schedule 1, Part 1, entry for Balsalazide in the form Capsule containing balsalazide sodium 750 mg [Maximum Quantity: 560; Number of Repeats: 5]**  
(a) omit from the column headed "Circumstances": **C14084**  
(b) insert in numerical order in the column headed "Circumstances": **C14306**  
(c) omit from the column headed "Purposes": **P14084** substitute: **P14306**
- [61] **Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) omit from the column headed "Circumstances" (all instances): **C14033**  
(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14251**

- 
- [62] **Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
- [63] **Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
- [64] **Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
- [65] **Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
- [66] **Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
- [67] **Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g [Maximum Quantity: 1; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances": C14091*
-

- 
- (b) *insert in numerical order in the column headed "Circumstances": C14236*
- [68] **Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g [Maximum Quantity: 2; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances": C14091*
- (b) *insert in numerical order in the column headed "Circumstances": C14236*
- (c) *omit from the column headed "Purposes": P14091*      *substitute: P14236*
- [69] **Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g [Maximum Quantity: 1; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances" (all instances): C14091*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14236*
- [70] **Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g [Maximum Quantity: 2; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances" (all instances): C14091*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14236*
- (c) *omit from the column headed "Purposes" (all instances): P14091*      *substitute (all instances): P14236*
- [71] **Schedule 1, Part 1, entry for Calcitriol in the form Capsule 0.25 microgram [Maximum Quantity: 100; Number of Repeats: 3]**
- (a) *omit from the column headed "Circumstances" (all instances): C14071 C14087 C14088 C14100 C14111*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14231 C14259 C14287 C14296 C14322*
- [72] **Schedule 1, Part 1, entry for Calcitriol in the form Capsule 0.25 microgram [Maximum Quantity: 200; Number of Repeats: 3]**
- (a) *omit from the column headed "Circumstances" (all instances): C14071 C14087 C14088 C14100 C14111*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14231 C14259 C14287 C14296 C14322*
- (c) *omit from the column headed "Purposes" (all instances): P14071 P14087 P14088 P14100 P14111*      *substitute (all instances): P14231 P14259 P14287 P14296 P14322*
- [73] **Schedule 1, Part 1, entry for Calcium in the form Tablet, chewable, 500 mg (as carbonate) [Maximum Quantity: 240; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances": C14054*
-

- 
- (b) *insert in numerical order in the column headed "Circumstances": C14228*
- [74] **Schedule 1, Part 1, entry for Calcium in the form Tablet, chewable, 500 mg (as carbonate) [Maximum Quantity: 480; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances": C14054*
- (b) *insert in numerical order in the column headed "Circumstances": C14228*
- (c) *omit from the column headed "Purposes": P14054 substitute: P14228*
- [75] **Schedule 1, Part 1, entry for Calcium in the form Tablet 600 mg (as carbonate) [Maximum Quantity: 240; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances": C14054*
- (b) *insert in numerical order in the column headed "Circumstances": C14228*
- [76] **Schedule 1, Part 1, entry for Calcium in the form Tablet 600 mg (as carbonate) [Maximum Quantity: 480; Number of Repeats: 1]**
- (a) *omit from the column headed "Circumstances": C14054*
- (b) *insert in numerical order in the column headed "Circumstances": C14228*
- (c) *omit from the column headed "Purposes": P14054 substitute: P14228*
- [77] **Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 4 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*
- [78] **Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 8 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*
- [79] **Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 16 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*
- [80] **Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 32 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*
-

- 
- [81] **Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [82] **Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*  
(c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [83] **Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [84] **Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*  
(c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [85] **Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [86] **Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
-

- 
- (c) omit from the column headed "Purposes" (all instances): **P14061** substitute (all instances): **P14255**
- [87] **Schedule 1, Part 1, entry for Carvedilol in the form Tablet 6.25 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14033 C14115**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14251 C14270**
- [88] **Schedule 1, Part 1, entry for Carvedilol in the form Tablet 6.25 mg [Maximum Quantity: 120; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14033 C14115**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14251 C14270**
- (c) omit from the column headed "Purposes" (all instances): **P14033 P14115** substitute (all instances): **P14251 P14270**
- [89] **Schedule 1, Part 1, entry for Carvedilol in the form Tablet 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14033 C14115**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14251 C14270**
- [90] **Schedule 1, Part 1, entry for Carvedilol in the form Tablet 12.5 mg [Maximum Quantity: 120; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14033 C14115**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14251 C14270**
- (c) omit from the column headed "Purposes" (all instances): **P14033 P14115** substitute (all instances): **P14251 P14270**
- [91] **Schedule 1, Part 1, entry for Carvedilol in the form Tablet 25 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14033 C14115**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14251 C14270**
- [92] **Schedule 1, Part 1, entry for Carvedilol in the form Tablet 25 mg [Maximum Quantity: 120; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14033 C14115**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14251 C14270**
- (c) omit from the column headed "Purposes" (all instances): **P14033 P14115** substitute (all instances): **P14251 P14270**
- [93] **Schedule 1, Part 1, entry for Chlortalidone in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 1]**
- omit from the column headed "Purposes": **P14141** substitute: **P14238**
-

**[94] Schedule 1, Part 1, entry for Clonidine in the form Tablet containing clonidine hydrochloride 100 micrograms [Maximum Quantity: 200; Number of Repeats: 5]**

**(a)** omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**(b)** insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                 |    |    |    |        |     |   |     |
|---|-----------------|----|----|----|--------|-----|---|-----|
| a | Clonidine Lupin | GQ | MP | NP | P14238 | 200 | 5 | 100 |
|---|-----------------|----|----|----|--------|-----|---|-----|

**[95] Schedule 1, Part 1, entry for Clonidine in the form Tablet containing clonidine hydrochloride 150 micrograms [Maximum Quantity: 200; Number of Repeats: 5]**

omit from the column headed "Purposes": **P14141** substitute: **P14238**

**[96] Schedule 1, Part 1, entry for Clopidogrel in the form Tablet 75 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[97] Schedule 1, Part 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate) [Maximum Quantity: 56; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[98] Schedule 1, Part 1, entry for Clopidogrel with aspirin in the form Tablet 75 mg (as hydrogen sulfate)-100 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[99] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 20; Number of Repeats: 0]**

**(a)** omit from the column headed "Circumstances": **C14078**

**(b)** insert in numerical order in the column headed "Circumstances": **C14308**

**[100] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 20; Number of Repeats: 1]**

**(a)** omit from the column headed "Circumstances": **C14078**

**(b)** insert in numerical order in the column headed "Circumstances": **C14308**

**[101] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 0]**

**(a)** omit from the column headed "Circumstances": **C14078**

**(b)** insert in numerical order in the column headed "Circumstances": **C14308**

- 
- [102] **Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14078*  
(b) *insert in numerical order in the column headed "Circumstances": C14308*
- [103] **Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 120; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14078*  
(b) *insert in numerical order in the column headed "Circumstances": C14308*  
(c) *omit from the column headed "Purposes": P14078* *substitute: P14308*
- [104] **Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14078*  
(b) *insert in numerical order in the column headed "Circumstances": C14308*
- [105] **Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate) [Maximum Quantity: 120; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14078*  
(b) *insert in numerical order in the column headed "Circumstances": C14308*  
(c) *omit from the column headed "Purposes": P14078* *substitute: P14308*
- [106] **Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [107] **Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [108] **Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 20 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [109] **Schedule 1, Part 1, entry for Enalapril with hydrochlorothiazide in the form Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14107*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14280*
-

- 
- [110] **Schedule 1, Part 1, entry for Enalapril with hydrochlorothiazide in the form Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14107*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14280*
  - (c) *omit from the column headed "Purposes" (all instances): P14107*      *substitute (all instances): P14280*
- [111] **Schedule 1, Part 1, entry for Eplerenone in the form Tablet 25 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14035*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14266*
- [112] **Schedule 1, Part 1, entry for Eplerenone in the form Tablet 25 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14035*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14266*
  - (c) *omit from the column headed "Purposes" (all instances): P14035*      *substitute (all instances): P14266*
- [113] **Schedule 1, Part 1, entry for Eplerenone in the form Tablet 50 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14035*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14266*
- [114] **Schedule 1, Part 1, entry for Eplerenone in the form Tablet 50 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14035*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14266*
  - (c) *omit from the column headed "Purposes" (all instances): P14035*      *substitute (all instances): P14266*
- [115] **Schedule 1, Part 1, entry for Ezetimibe in the form Tablet 10 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14135 C14136 C14137*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14249 C14283 C14310*
- [116] **Schedule 1, Part 1, entry for Ezetimibe in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14135 C14136 C14137*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14249 C14283 C14310*
-

---

(c) omit from the column headed "Purposes" (all instances): **P14135 P14136 P14137** substitute (all instances): **P14249 P14283 P14310**

[117] **Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]**

(a) insert in numerical order in the column headed "Circumstances" (all instances): **C14350**

(b) insert in the column headed "Purposes" (all instances): **P7958**

[118] **Schedule 1, Part 1, after entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]**

insert:

|   |                               |    |       |              |        |   |   |   |
|---|-------------------------------|----|-------|--------------|--------|---|---|---|
| a | Ezalo Composite Pack 10mg+5mg | AF | MP NP | C7958 C14350 | P14350 | 2 | 5 | 1 |
| a | Rosuzet Composite Pack        | AL | MP NP | C7958 C14350 | P14350 | 2 | 5 | 1 |

[119] **Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]**

(a) omit from the column headed "Circumstances" (all instances): **C14057**

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14284**

[120] **Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]**

(a) omit from the column headed "Circumstances" (all instances): **C14057**

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14284**

(c) omit from the column headed "Purposes" (all instances): **P14057** substitute (all instances): **P14284**

[121] **Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]**

(a) omit from the column headed "Circumstances" (all instances): **C14057**

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14284**

- 
- [122] **Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14057*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*
  - (c) *omit from the column headed "Purposes" (all instances): P14057*      *substitute (all instances): P14284*
- [123] **Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14057*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*
- [124] **Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14057*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*
  - (c) *omit from the column headed "Purposes" (all instances): P14057*      *substitute (all instances): P14284*
- [125] **Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14056*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14269*
- [126] **Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14056*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14269*
  - (c) *omit from the column headed "Purposes" (all instances): P14056*      *substitute (all instances): P14269*
- [127] **Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *insert in numerical order in the column headed "Circumstances" (all instances): C14348*
  - (b) *insert in the column headed "Purposes" (all instances): P7957*
-

- [128] **Schedule 1, Part 1, after entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]**

*insert:*

|   |                                     |    |       |              |        |    |   |    |
|---|-------------------------------------|----|-------|--------------|--------|----|---|----|
| a | Atozet                              | AF | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 |
| a | Ezetast                             | XT | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 |
| a | Ezetimibe/Atorvasta<br>tin GH 10/20 | GQ | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 |

- [129] **Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 30; Number of Repeats: 5]**

- (a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*

- [130] **Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 60; Number of Repeats: 5]**

- (a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*  
(c) *omit from the column headed "Purposes" (all instances): P14057* *substitute (all instances): P14284*

- [131] **Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 30; Number of Repeats: 5]**

- (a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*

- [132] **Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 60; Number of Repeats: 5]**

- (a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*  
(c) *omit from the column headed "Purposes" (all instances): P14057* *substitute (all instances): P14284*

- [133] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 30; Number of Repeats: 5]**

- (a) *omit from the column headed "Circumstances" (all instances): C14056*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14269*

- 
- [134] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14056*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14269*  
(c) *omit from the column headed "Purposes" (all instances): P14056*      *substitute (all instances): P14269*
- [135] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14056*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14269*
- [136] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14056*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14269*  
(c) *omit from the column headed "Purposes" (all instances): P14056*      *substitute (all instances): P14269*
- [137] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*
- [138] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*  
(c) *omit from the column headed "Purposes" (all instances): P14057*      *substitute (all instances): P14284*
- [139] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*
- [140] **Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14057*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14284*  
(c) *omit from the column headed "Purposes" (all instances): P14057*      *substitute (all instances): P14284*
-

- [141] **Schedule 1, Part 1, entry for Febuxostat in the form Tablet 80 mg [Maximum Quantity: 28; Number of Repeats: 5]**  
 (a) omit from the column headed "Circumstances": **C14121**  
 (b) insert in numerical order in the column headed "Circumstances": **C14313**
- [142] **Schedule 1, Part 1, entry for Febuxostat in the form Tablet 80 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
 (a) omit from the column headed "Circumstances": **C14121**  
 (b) insert in numerical order in the column headed "Circumstances": **C14313**  
 (c) omit from the column headed "Purposes": **P14121** substitute: **P14313**
- [143] **Schedule 1, Part 1, entry for Felodipine in the form Tablet 2.5 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]**  
 (a) omit from the column headed "Purposes" (all instances): **P14141**  
 (b) insert in numerical order in the column headed "Purposes" (all instances): **P14238**
- [144] **Schedule 1, Part 1, entry for Felodipine in the form Tablet 5 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]**  
 (a) omit from the column headed "Purposes" (all instances): **P14141**  
 (b) insert in numerical order in the column headed "Purposes" (all instances): **P14238**
- [145] **Schedule 1, Part 1, entry for Felodipine in the form Tablet 10 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]**  
 (a) omit from the column headed "Purposes" (all instances): **P14141**  
 (b) insert in numerical order in the column headed "Purposes" (all instances): **P14238**
- [146] **Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 48 mg**  
 omit:

|   |                     |    |    |       |    |    |    |
|---|---------------------|----|----|-------|----|----|----|
| a | APO-Fenofibrate     | TX | MP | P7640 | 60 | 11 | 60 |
| a | Fenofibrate Cipla   | LR | MP | P7640 | 60 | 11 | 60 |
| a | Fenofibrate Mylan   | AF | MP | P7640 | 60 | 11 | 60 |
| a | FENOFIBRATE<br>RBX  | RA | MP | P7640 | 60 | 11 | 60 |
| a | Fenofibrate Viartis | AL | MP | P7640 | 60 | 11 | 60 |

|   |         |    |    |       |    |    |    |
|---|---------|----|----|-------|----|----|----|
| a | Lipidil | GO | MP | P7640 | 60 | 11 | 60 |
|---|---------|----|----|-------|----|----|----|

**[147] Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 48 mg [Maximum Quantity: 120; Number of Repeats: 5]**

**(a)** omit:

|   |                   |    |    |        |     |   |    |
|---|-------------------|----|----|--------|-----|---|----|
| a | Fenofibrate Mylan | AF | MP | P14141 | 120 | 5 | 60 |
|---|-------------------|----|----|--------|-----|---|----|

**(b)** omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[148] Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 145 mg**

omit:

|   |                                |    |    |       |    |    |    |
|---|--------------------------------|----|----|-------|----|----|----|
| a | APO-Fenofibrate                | TX | MP | P7640 | 30 | 11 | 30 |
| a | Blooms the Chemist Fenofibrate | IB | MP | P7640 | 30 | 11 | 30 |
| a | Fenocol                        | YC | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Cipla              | LR | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Mylan              | AF | MP | P7640 | 30 | 11 | 30 |
| a | FENOFIBRATE RBX                | RA | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Sandoz             | SZ | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Viatris            | AL | MP | P7640 | 30 | 11 | 30 |
| a | Lipidil                        | GO | MP | P7640 | 30 | 11 | 30 |

**[149] Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 145 mg [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** omit:

|   |                   |    |    |        |    |   |    |
|---|-------------------|----|----|--------|----|---|----|
| a | Fenofibrate Mylan | AF | MP | P14141 | 60 | 5 | 30 |
|---|-------------------|----|----|--------|----|---|----|

**(b)** omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

---

**[150] Schedule 1, Part 1, entry for Fluvastatin**

*omit:*

|  |  |  |  |    |       |    |    |    |
|--|--|--|--|----|-------|----|----|----|
|  |  |  |  | MP | P7598 | 28 | 11 | 28 |
|--|--|--|--|----|-------|----|----|----|

**[151] Schedule 1, Part 1, entry for Fluvastatin in the form Tablet (prolonged release) 80 mg (as sodium) [Maximum Quantity: 56; Number of Repeats: 5]**

*omit from the column headed "Purposes":* **P14141** *substitute:* **P14238**

**[152] Schedule 1, Part 1, entry for Furosemide in the form Oral solution 10 mg per mL, 30 mL [Maximum Quantity: 2; Number of Repeats: 3]**

*omit from the column headed "Purposes":* **P14141** *substitute:* **P14238**

**[153] Schedule 1, Part 1, entry for Furosemide in the form Tablet 20 mg [Maximum Quantity: 200; Number of Repeats: 1]**

*omit from the column headed "Purposes" (all instances):* **P14141** *substitute (all instances):* **P14238**

**[154] Schedule 1, Part 1, entry for Furosemide in the form Tablet 40 mg [Maximum Quantity: 200; Number of Repeats: 1]**

*omit from the column headed "Purposes" (all instances):* **P14141** *substitute (all instances):* **P14238**

**[155] Schedule 1, Part 1, entry for Furosemide in the form Tablet 500 mg [Maximum Quantity: 100; Number of Repeats: 3]**

*omit from the column headed "Purposes":* **P14141** *substitute:* **P14238**

**[156] Schedule 1, Part 1, entry for Gemfibrozil**

*omit:*

|  |   |         |    |    |       |    |    |    |
|--|---|---------|----|----|-------|----|----|----|
|  | a | Ausgem  | RW | MP | P7640 | 60 | 11 | 60 |
|  | a | Lipigem | AF | MP | P7640 | 60 | 11 | 60 |

**[157] Schedule 1, Part 1, after entry for Gemfibrozil in the form Tablet 600 mg**

*insert:*

|  |   |         |    |       |        |     |   |    |
|--|---|---------|----|-------|--------|-----|---|----|
|  | a | Ausgem  | RW | MP NP | P14238 | 120 | 5 | 60 |
|  | a | Lipigem | AF | MP NP | P14238 | 120 | 5 | 60 |

- [158] **Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Transdermal patch 25 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
omit from the column headed "Purposes": **P14141** substitute: **P14238**
- [159] **Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Transdermal patch 50 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
omit from the column headed "Purposes": **P14141** substitute: **P14238**
- [160] **Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Sublingual spray (pump pack) 400 micrograms per dose, 200 doses [Maximum Quantity: 2; Number of Repeats: 5]**  
omit from the column headed "Purposes": **P14141** substitute: **P14238**
- [161] **Schedule 1, Part 1, entry for Hydralazine in each of the forms: Tablet containing hydralazine hydrochloride 25 mg; and Tablet containing hydralazine hydrochloride 50 mg**  
omit:

|  |       |        |     |   |     |
|--|-------|--------|-----|---|-----|
|  | MP NP | P14141 | 400 | 2 | 100 |
|--|-------|--------|-----|---|-----|

- [162] **Schedule 1, Part 1, entry for Hydrochlorothiazide in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 1]**  
omit from the column headed "Purposes": **P14141** substitute: **P14238**
- [163] **Schedule 1, Part 1, entry for Hydrochlorothiazide with amiloride in the form Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg [Maximum Quantity: 200; Number of Repeats: 1]**  
omit from the column headed "Purposes": **P14141** substitute: **P14238**
- [164] **Schedule 1, Part 1, entry for Indapamide in the form Tablet containing indapamide hemihydrate 1.5 mg (sustained release) [Maximum Quantity: 180; Number of Repeats: 1]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**
- [165] **Schedule 1, Part 1, entry for Indapamide in the form Tablet containing indapamide hemihydrate 2.5 mg [Maximum Quantity: 180; Number of Repeats: 1]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**
- [166] **Schedule 1, Part 1, entry for Irbesartan in the form Tablet 75 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

- 
- [167] **Schedule 1, Part 1, entry for Irbesartan in the form Tablet 150 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141*      *substitute (all instances): P14238*
- [168] **Schedule 1, Part 1, entry for Irbesartan in the form Tablet 300 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141*      *substitute (all instances): P14238*
- [169] **Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 150 mg-12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [170] **Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 150 mg-12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*  
(c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [171] **Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [172] **Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*  
(c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [173] **Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*
-

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**

[174] **Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 60; Number of Repeats: 5]**

(a) omit from the column headed "Circumstances" (all instances): **C14061**

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**

(c) omit from the column headed "Purposes" (all instances): **P14061** substitute (all instances): **P14255**

[175] **Schedule 1, Part 1, entry for Isosorbide dinitrate in the form Tablet 5 mg (sublingual) [Maximum Quantity: 400; Number of Repeats: 2]**  
omit from the column headed "Purposes": **P14141** substitute: **P14238**

[176] **Schedule 1, Part 1, entry for Isosorbide mononitrate in the form Tablet 60 mg (sustained release) [Maximum Quantity: 60; Number of Repeats: 5]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

[177] **Schedule 1, Part 1, after entry for Isosorbide mononitrate in the form Tablet 120 mg (sustained release)**  
insert:

|   |                |    |       |        |    |   |    |
|---|----------------|----|-------|--------|----|---|----|
| a | Imdur 120 mg   | IX | MP NP | P14238 | 60 | 5 | 30 |
| a | Monodur 120 mg | IY | MP NP | P14238 | 60 | 5 | 30 |

[178] **Schedule 1, Part 1, entry for Labetalol**  
omit:

|  |  |  |       |        |     |   |     |
|--|--|--|-------|--------|-----|---|-----|
|  |  |  | MP NP | P14141 | 200 | 5 | 100 |
|--|--|--|-------|--------|-----|---|-----|

[179] **Schedule 1, Part 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 10 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

[180] **Schedule 1, Part 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 20 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

- 
- [181] **Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*
- [182] **Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*  
(c) *omit from the column headed "Purposes": P14049* *substitute: P14245*
- [183] **Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*
- [184] **Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*  
(c) *omit from the column headed "Purposes": P14049* *substitute: P14245*
- [185] **Schedule 1, Part 1, entry for Lisinopril in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [186] **Schedule 1, Part 1, entry for Lisinopril in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [187] **Schedule 1, Part 1, entry for Lisinopril in the form Tablet 20 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
-

- 
- [188] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 500 mg per sachet [Maximum Quantity: 200; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances": C14260*
- [189] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 500 mg per sachet [Maximum Quantity: 400; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances": C14260*
  - (c) *omit from the column headed "Purposes": P14023 substitute: P14260*
- [190] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1 g per sachet [Maximum Quantity: 100; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances": C14260*
- [191] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1 g per sachet [Maximum Quantity: 200; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances": C14260*
  - (c) *omit from the column headed "Purposes": P14023 substitute: P14260*
- [192] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet [Maximum Quantity: 100; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14023 C14024*
  - (b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*
- [193] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet [Maximum Quantity: 200; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14023 C14024*
  - (b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*
-

- 
- (c) omit from the column headed "Purposes": **P14023 P14024** substitute: **P14229 P14260**
- [194] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1.5 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14023**
- (b) insert in numerical order in the column headed "Circumstances": **C14260**
- [195] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1.5 g per sachet [Maximum Quantity: 120; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14023**
- (b) insert in numerical order in the column headed "Circumstances": **C14260**
- (c) omit from the column headed "Purposes": **P14023** substitute: **P14260**
- [196] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 2 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14023 C14024**
- (b) insert in numerical order in the column headed "Circumstances": **C14229 C14260**
- [197] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 2 g per sachet [Maximum Quantity: 120; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14023 C14024**
- (b) insert in numerical order in the column headed "Circumstances": **C14229 C14260**
- (c) omit from the column headed "Purposes": **P14023 P14024** substitute: **P14229 P14260**
- [198] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 3 g per sachet [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14023**
- (b) insert in numerical order in the column headed "Circumstances": **C14260**
- [199] **Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 3 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14023**
-

- 
- (b) *insert in numerical order in the column headed "Circumstances":* **C14260**
- (c) *omit from the column headed "Purposes":* **P14023** *substitute:* **P14260**
- [200] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14023**
- (b) *insert in numerical order in the column headed "Circumstances":* **C14260**
- [201] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14023**
- (b) *insert in numerical order in the column headed "Circumstances":* **C14260**
- (c) *omit from the column headed "Purposes":* **P14023** *substitute:* **P14260**
- [202] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 250 mg (enteric coated) [Maximum Quantity: 100; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14023 C14024**
- (b) *insert in numerical order in the column headed "Circumstances":* **C14229 C14260**
- [203] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 250 mg (enteric coated) [Maximum Quantity: 200; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14023 C14024**
- (b) *insert in numerical order in the column headed "Circumstances":* **C14229 C14260**
- (c) *omit from the column headed "Purposes":* **P14023 P14024** *substitute:* **P14229 P14260**
- [204] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 200; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14023 C14024**
- (b) *insert in numerical order in the column headed "Circumstances":* **C14229 C14260**
- [205] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 400; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14023 C14024**
- (b) *insert in numerical order in the column headed "Circumstances":* **C14229 C14260**
- (c) *omit from the column headed "Purposes":* **P14023 P14024** *substitute:* **P14229 P14260**
-

- 
- [206] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (prolonged release) [Maximum Quantity: 200; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14023 C14024*  
(b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*
- [207] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (prolonged release) [Maximum Quantity: 400; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14023 C14024*  
(b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*  
(c) *omit from the column headed "Purposes": P14023 P14024* *substitute: P14229 P14260*
- [208] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 800 mg (enteric coated) [Maximum Quantity: 90; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14023*  
(b) *insert in numerical order in the column headed "Circumstances": C14260*
- [209] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 800 mg (enteric coated) [Maximum Quantity: 180; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14023*  
(b) *insert in numerical order in the column headed "Circumstances": C14260*  
(c) *omit from the column headed "Purposes": P14023* *substitute: P14260*
- [210] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (enteric coated) [Maximum Quantity: 120; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14023 C14024*  
(b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*
- [211] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (enteric coated) [Maximum Quantity: 240; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14023 C14024*  
(b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*  
(c) *omit from the column headed "Purposes": P14023 P14024* *substitute: P14229 P14260*
- [212] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (prolonged release) [Maximum Quantity: 120; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14023 C14024*  
(b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*
-

- 
- [213] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (prolonged release) [Maximum Quantity: 240; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14023 C14024*
  - (b) *insert in numerical order in the column headed "Circumstances": C14229 C14260*
  - (c) *omit from the column headed "Purposes": P14023 P14024*      *substitute: P14229 P14260*
- [214] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.2 g (prolonged release) [Maximum Quantity: 120; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" for the brands "Mesalazine 1.2 TAKEDA" and "Mezavant": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances" for the brands "Mesalazine 1.2 TAKEDA" and "Mezavant": C14260*
  - (c) *omit from the column headed "Circumstances" for the brand "MESALZ": C14120*
  - (d) *insert in numerical order in the column headed "Circumstances" for the brand "MESALZ": C14260*
- [215] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.2 g (prolonged release) [Maximum Quantity: 240; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" for the brands "Mesalazine 1.2 TAKEDA" and "Mezavant": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances" for the brands "Mesalazine 1.2 TAKEDA" and "Mezavant": C14260*
  - (c) *omit from the column headed "Circumstances" for the brand "MESALZ": C14120*
  - (d) *insert in numerical order in the column headed "Circumstances" for the brand "MESALZ": C14260*
  - (e) *omit from the column headed "Purposes" for the brands "Mesalazine 1.2 TAKEDA" and "Mezavant": P14023*      *substitute: P14260*
  - (f) *omit from the column headed "Purposes" for the brand "MESALZ": P14120*      *substitute: P14260*
- [216] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.6 g (enteric coated) [Maximum Quantity: 120; Number of Repeats: 4]**
- (a) *omit from the column headed "Circumstances": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances": C14260*
- [217] **Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.6 g (enteric coated) [Maximum Quantity: 240; Number of Repeats: 4]**
- (a) *omit from the column headed "Circumstances": C14023*
  - (b) *insert in numerical order in the column headed "Circumstances": C14260*
  - (c) *omit from the column headed "Purposes": P14023*      *substitute: P14260*
- [218] **Schedule 1, Part 1, entry for Methyldopa in the form Tablet 250 mg (as sesquihydrate) [Maximum Quantity: 100; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14141*
-

---

(b) omit from the column headed "Purposes": **P13887**

**[219] Schedule 1, Part 1, entry for Methyldopa**

*omit:*

|  |       |               |        |     |   |     |
|--|-------|---------------|--------|-----|---|-----|
|  | MP NP | C13887 C14141 | P14141 | 200 | 5 | 100 |
|--|-------|---------------|--------|-----|---|-----|

**[220] Schedule 1, Part 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 50 mg [Maximum Quantity: 200; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances):* **P14141**      *substitute (all instances):* **P14238**

**[221] Schedule 1, Part 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 100 mg [Maximum Quantity: 120; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances):* **P14141**      *substitute (all instances):* **P14238**

**[222] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 47.5 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]**

(a) *omit from the column headed "Circumstances" (all instances):* **C14033**

(b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14251**

**[223] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 47.5 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]**

(a) *omit from the column headed "Circumstances" (all instances):* **C14033**

(b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14251**

(c) *omit from the column headed "Purposes" (all instances):* **P14033**      *substitute (all instances):* **P14251**

**[224] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 95 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]**

(a) *omit from the column headed "Circumstances" (all instances):* **C14033**

(b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14251**

- 
- [225] **Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 95 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
- [226] **Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 190 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
- [227] **Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 190 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
- [228] **Schedule 1, Part 1, entry for Moxonidine in the form Tablet 200 micrograms [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14037*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14289*
- [229] **Schedule 1, Part 1, entry for Moxonidine in the form Tablet 200 micrograms [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14037*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14289*
  - (c) *omit from the column headed "Purposes" (all instances): P14037*      *substitute (all instances): P14289*
- [230] **Schedule 1, Part 1, entry for Moxonidine in the form Tablet 400 micrograms [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14037*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14289*
-

- 
- [231] **Schedule 1, Part 1, entry for Moxonidine in the form Tablet 400 micrograms [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14037*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14289*
  - (c) *omit from the column headed "Purposes" (all instances): P14037*      *substitute (all instances): P14289*
- [232] **Schedule 1, Part 1, entry for Nebivolol in the form Tablet 1.25 mg (as hydrochloride) [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
- [233] **Schedule 1, Part 1, entry for Nebivolol in the form Tablet 1.25 mg (as hydrochloride) [Maximum Quantity: 112; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
- [234] **Schedule 1, Part 1, entry for Nebivolol in the form Tablet 5 mg (as hydrochloride) [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
- [235] **Schedule 1, Part 1, entry for Nebivolol in the form Tablet 5 mg (as hydrochloride) [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
- [236] **Schedule 1, Part 1, entry for Nebivolol in the form Tablet 10 mg (as hydrochloride) [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
- [237] **Schedule 1, Part 1, entry for Nebivolol in the form Tablet 10 mg (as hydrochloride) [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14033*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14251*
  - (c) *omit from the column headed "Purposes" (all instances): P14033*      *substitute (all instances): P14251*
-

- 
- [238] **Schedule 1, Part 1, entry for Nicorandil in the form Tablets 10 mg, 60 [Maximum Quantity: 2; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [239] **Schedule 1, Part 1, entry for Nicorandil in the form Tablets 20 mg, 60 [Maximum Quantity: 2; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [240] **Schedule 1, Part 1, entry for Nifedipine in the form Tablet 30 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [241] **Schedule 1, Part 1, entry for Nifedipine in the form Tablet 60 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [242] **Schedule 1, Part 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [243] **Schedule 1, Part 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [244] **Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14043*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- [245] **Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14043*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*  
(c) *omit from the column headed "Purposes" (all instances): P14043* *substitute (all instances): P14257*
-

---

**[246] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances" (all instances): **C14043**

**(b)** omit from the column headed "Purposes" (all instances): **P4373**

**[247] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)**

omit:

|   |                                      |    |       |              |        |    |   |    |
|---|--------------------------------------|----|-------|--------------|--------|----|---|----|
| a | OLMEKAR                              | RW | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |
| a | Olmesartan/Amlodipine - MYL 40/5     | AF | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |
| a | Olmesartan/Amlodipine 40/5 APOTEX    | TX | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |
| a | Pharmacor Olmesartan Amlodipine 40/5 | CR | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |
| a | Sevikar 40/5                         | AL | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |

**[248] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances" (all instances): **C14043**

**(b)** omit from the column headed "Purposes" (all instances): **P4373**

**[249] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]**

omit:

|   |                                   |    |       |              |        |    |   |    |
|---|-----------------------------------|----|-------|--------------|--------|----|---|----|
| a | OLMEKAR                           | RW | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |
| a | Olmesartan/Amlodipine - MYL 40/10 | AF | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |

|   |                                             |    |       |              |        |    |   |    |
|---|---------------------------------------------|----|-------|--------------|--------|----|---|----|
| a | Olmesartan/Amlodipine 40/10<br>APOTEX       | TX | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |
| a | Pharmacor<br>Olmesartan<br>Amlodipine 40/10 | CR | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |
| a | Sevikar 40/10                               | AL | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 |

**[250] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14062**  
(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14272**

**[251] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14062**  
(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14272**  
(c) omit from the column headed "Purposes" (all instances): **P14062** substitute (all instances): **P14272**

**[252] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14062**  
(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14272**

**[253] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14062**  
(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14272**  
(c) omit from the column headed "Purposes" (all instances): **P14062** substitute (all instances): **P14272**

- 
- [254] **Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- [255] **Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
  - (c) *omit from the column headed "Purposes" (all instances): P14062*      *substitute (all instances): P14272*
- [256] **Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
- [257] **Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14272*
  - (c) *omit from the column headed "Purposes" (all instances): P14062*      *substitute (all instances): P14272*
- [258] **Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14062*
  - (b) *omit from the column headed "Purposes" (all instances): P4311*
- [259] **Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg**
- omit:*
-

|   |                                                |    |       |              |        |    |   |    |
|---|------------------------------------------------|----|-------|--------------|--------|----|---|----|
| a | APO-Olmesartan/A<br>mlodipine/HCTZ<br>40/10/25 | TX | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 |
| a | Olamlo HCT<br>40/10/25                         | AL | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 |
| a | Olmekar HCT<br>40/10/25                        | RF | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 |
| a | Sevikar HCT<br>40/10/25                        | AF | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 |

**[260] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**

**[261] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**
- (c) omit from the column headed "Purposes" (all instances): **P14061** substitute (all instances): **P14255**

**[262] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**

**[263] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**
- (c) omit from the column headed "Purposes" (all instances): **P14061** substitute (all instances): **P14255**

- [264] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg *[Maximum Quantity: 30; Number of Repeats: 5]*
- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**
- [265] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg *[Maximum Quantity: 60; Number of Repeats: 5]*
- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**
- (c) omit from the column headed "Purposes" (all instances): **P14061** substitute (all instances): **P14255**
- [266] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity

omit:

|    |       |     |    |     |
|----|-------|-----|----|-----|
| MP | P5779 | 500 | 21 | 100 |
|----|-------|-----|----|-----|

- [267] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity *[Maximum Quantity: 1000; Number of Repeats: 10]*
- omit from the column headed "Purposes": **P14141** substitute: **P14238**
- [268] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity

omit:

|    |       |     |    |     |
|----|-------|-----|----|-----|
| MP | P5779 | 200 | 21 | 100 |
|----|-------|-----|----|-----|

- [269] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity *[Maximum Quantity: 400; Number of Repeats: 10]*
- omit from the column headed "Purposes": **P14141** substitute: **P14238**

- [270] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity

omit:

|    |       |     |    |     |
|----|-------|-----|----|-----|
| MP | P5779 | 200 | 21 | 100 |
|----|-------|-----|----|-----|

- [271] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity [Maximum Quantity: 400; Number of Repeats: 10]

omit from the column headed "Purposes": P14141 substitute: P14238

- [272] Schedule 1, Part 1, entry for Pancreatic extract in the form Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g

omit:

|    |       |   |    |   |
|----|-------|---|----|---|
| MP | P5779 | 3 | 21 | 1 |
|----|-------|---|----|---|

- [273] Schedule 1, Part 1, entry for Pancreatic extract in the form Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g [Maximum Quantity: 6; Number of Repeats: 10]

omit from the column headed "Purposes": P14141 substitute: P14238

- [274] Schedule 1, Part 1, entry for Penicillamine in the form Tablet 125 mg [Maximum Quantity: 200; Number of Repeats: 1]

omit from the column headed "Purposes": P14141 substitute: P14238

- [275] Schedule 1, Part 1, entry for Penicillamine in the form Tablet 250 mg [Maximum Quantity: 200; Number of Repeats: 1]

omit from the column headed "Purposes": P14141 substitute: P14238

- [276] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril erbumine 2 mg [Maximum Quantity: 60; Number of Repeats: 5]

omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238

- [277] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril arginine 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]

(a) omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238

(b) insert in columns in the order indicated, and in alphabetical order for the column headed "Brand":

|  |                             |    |       |        |    |   |    |
|--|-----------------------------|----|-------|--------|----|---|----|
|  | APX-Perindopril<br>Arginine | XT | MP NP | P14238 | 60 | 5 | 30 |
|--|-----------------------------|----|-------|--------|----|---|----|

**[278] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril erbumine 4 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[279] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril arginine 5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** *omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**(b)** *insert in columns in the order indicated, and in alphabetical order for the column headed "Brand":*

|  |                             |    |       |        |    |   |    |
|--|-----------------------------|----|-------|--------|----|---|----|
|  | APX-Perindopril<br>Arginine | XT | MP NP | P14238 | 60 | 5 | 30 |
|--|-----------------------------|----|-------|--------|----|---|----|

**[280] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril erbumine 8 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[281] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril arginine 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** *omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**(b)** *insert in columns in the order indicated, and in alphabetical order for the column headed "Brand":*

|  |                             |    |       |        |    |   |    |
|--|-----------------------------|----|-------|--------|----|---|----|
|  | APX-Perindopril<br>Arginine | XT | MP NP | P14238 | 60 | 5 | 30 |
|--|-----------------------------|----|-------|--------|----|---|----|

**[282] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]**

**(a)** *omit from the column headed "Circumstances" (all instances): C14049 C14068*

**(b)** *insert in numerical order in the column headed "Circumstances" (all instances): C14245 C14246*

[283] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]

- (a) omit from the column headed "Circumstances" (all instances): C14049 C14068  
(b) insert in numerical order in the column headed "Circumstances" (all instances): C14245 C14246  
(c) omit from the column headed "Purposes" (all instances): P14049 P14068 substitute (all instances): P14245 P14246  
(d) insert in columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                                               |    |    |    |                              |               |    |   |    |
|---|-----------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|
| a | APX-Perindopril<br>Arginine/Amlodipine<br>5/5 | XT | MP | NP | C4398 C4418<br>C14245 C14246 | P14245 P14246 | 60 | 5 | 30 |
|---|-----------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|

[284] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]

- (a) omit from the column headed "Circumstances" (all instances): C14049 C14068  
(b) insert in numerical order in the column headed "Circumstances" (all instances): C14245 C14246

[285] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]

- (a) omit from the column headed "Circumstances" (all instances): C14049 C14068  
(b) insert in numerical order in the column headed "Circumstances" (all instances): C14245 C14246  
(c) omit from the column headed "Purposes" (all instances): P14049 P14068 substitute (all instances): P14245 P14246  
(d) insert in columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                                                |    |    |    |                              |               |    |   |    |
|---|------------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|
| a | APX-Perindopril<br>Arginine/Amlodipine<br>5/10 | XT | MP | NP | C4398 C4418<br>C14245 C14246 | P14245 P14246 | 60 | 5 | 30 |
|---|------------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|

[286] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]

- (a) omit from the column headed "Circumstances" (all instances): C14049 C14068  
(b) insert in numerical order in the column headed "Circumstances" (all instances): C14245 C14246

**[287] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances" (all instances): **C14049 C14068**

**(b)** insert in numerical order in the column headed "Circumstances" (all instances): **C14245 C14246**

**(c)** omit from the column headed "Purposes" (all instances): **P14049 P14068** substitute (all instances): **P14245 P14246**

**(d)** insert in columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                                                |    |    |    |                              |               |    |   |    |
|---|------------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|
| a | APX-Perindopril<br>Arginine/Amlodipine<br>10/5 | XT | MP | NP | C4398 C4418<br>C14245 C14246 | P14245 P14246 | 60 | 5 | 30 |
|---|------------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|

**[288] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances" (all instances): **C14049 C14068**

**(b)** insert in numerical order in the column headed "Circumstances" (all instances): **C14245 C14246**

**[289] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances" (all instances): **C14049 C14068**

**(b)** insert in numerical order in the column headed "Circumstances" (all instances): **C14245 C14246**

**(c)** omit from the column headed "Purposes" (all instances): **P14049 P14068** substitute (all instances): **P14245 P14246**

**(d)** insert in columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                                                 |    |    |    |                              |               |    |   |    |
|---|-------------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|
| a | APX-Perindopril<br>Arginine/Amlodipine<br>10/10 | XT | MP | NP | C4398 C4418<br>C14245 C14246 | P14245 P14246 | 60 | 5 | 30 |
|---|-------------------------------------------------|----|----|----|------------------------------|---------------|----|---|----|

**[290] Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

- 
- [291] **Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14098*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14267*
- [292] **Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14098*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14267*  
(c) *omit from the column headed "Purposes" (all instances): P14098*      *substitute (all instances): P14267*
- [293] **Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14098*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14267*
- [294] **Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14098*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14267*  
(c) *omit from the column headed "Purposes" (all instances): P14098*      *substitute (all instances): P14267*
- [295] **Schedule 1, Part 1, entry for Potassium chloride in the form Tablet 600 mg (sustained release) [Maximum Quantity: 400; Number of Repeats: 1]**  
*omit from the column headed "Purposes": P14141*      *substitute: P14238*
- [296] **Schedule 1, Part 1, entry for Potassium chloride with potassium bicarbonate in the form Tablet, effervescent, 14 mmol potassium and 8 mmol chloride [Maximum Quantity: 120; Number of Repeats: 1]**  
*omit from the column headed "Purposes": P14141*      *substitute: P14238*
- [297] **Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg**  
*omit:*
-

|   |                    |    |    |       |    |    |    |
|---|--------------------|----|----|-------|----|----|----|
| a | APO-Pravastatin    | TX | MP | P7598 | 30 | 11 | 30 |
| a | APX-Pravastatin    | TY | MP | P7598 | 30 | 11 | 30 |
| a | Cholstat 10        | AF | MP | P7598 | 30 | 11 | 30 |
| a | Lipostat 10        | RF | MP | P7598 | 30 | 11 | 30 |
| a | Pravachol          | RW | MP | P7598 | 30 | 11 | 30 |
| a | Pravastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |

**[298] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[299] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg**

*omit:*

|   |                    |    |    |       |    |    |    |
|---|--------------------|----|----|-------|----|----|----|
| a | APO-Pravastatin    | TX | MP | P7598 | 30 | 11 | 30 |
| a | APX-Pravastatin    | TY | MP | P7598 | 30 | 11 | 30 |
| a | Cholstat 20        | AF | MP | P7598 | 30 | 11 | 30 |
| a | Lipostat 20        | RF | MP | P7598 | 30 | 11 | 30 |
| a | Pravachol          | RW | MP | P7598 | 30 | 11 | 30 |
| a | Pravastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |

**[300] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[301] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg**

*omit:*

|   |                 |    |    |       |    |    |    |
|---|-----------------|----|----|-------|----|----|----|
| a | APO-Pravastatin | TX | MP | P7598 | 30 | 11 | 30 |
|---|-----------------|----|----|-------|----|----|----|

|   |                    |    |    |       |    |    |    |
|---|--------------------|----|----|-------|----|----|----|
| a | APX-Pravastatin    | TY | MP | P7598 | 30 | 11 | 30 |
| a | Cholstat 40        | AF | MP | P7598 | 30 | 11 | 30 |
| a | Lipostat 40        | RF | MP | P7598 | 30 | 11 | 30 |
| a | Pravachol          | RW | MP | P7598 | 30 | 11 | 30 |
| a | Pravastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |

**[302] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[303] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 80 mg**

*omit:*

|   |                 |    |    |       |    |    |    |
|---|-----------------|----|----|-------|----|----|----|
| a | APO-Pravastatin | TX | MP | P7598 | 30 | 11 | 30 |
| a | APX-Pravastatin | TY | MP | P7598 | 30 | 11 | 30 |
| a | Lipostat 80     | RF | MP | P7598 | 30 | 11 | 30 |
| a | Pravachol       | RW | MP | P7598 | 30 | 11 | 30 |

**[304] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 80 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[305] Schedule 1, Part 1, entry for Prazosin in the form Tablet 1 mg (as hydrochloride) [Maximum Quantity: 200; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[306] Schedule 1, Part 1, entry for Prazosin in the form Tablet 2 mg (as hydrochloride) [Maximum Quantity: 200; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[307] Schedule 1, Part 1, entry for Prazosin in the form Tablet 5 mg (as hydrochloride) [Maximum Quantity: 200; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

---

**[308] Schedule 1, Part 1, entry for Probenecid**

*omit:*

|  |  |  |  |       |        |     |   |     |
|--|--|--|--|-------|--------|-----|---|-----|
|  |  |  |  | MP NP | P14141 | 200 | 5 | 100 |
|--|--|--|--|-------|--------|-----|---|-----|

**[309] Schedule 1, Part 1, entry for Propranolol in the form Tablet containing propranolol hydrochloride 10 mg [Maximum Quantity: 200; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141*      *substitute (all instances): P14238*

**[310] Schedule 1, Part 1, entry for Propranolol in the form Tablet containing propranolol hydrochloride 40 mg [Maximum Quantity: 200; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141*      *substitute (all instances): P14238*

**[311] Schedule 1, Part 1, entry for Quinapril in the form Tablet 5 mg (as hydrochloride)**

*omit:*

|  |   |          |    |       |        |    |   |    |
|--|---|----------|----|-------|--------|----|---|----|
|  | a | Accupril | PF | MP NP | P14141 | 60 | 5 | 30 |
|  | a | ACQUIN   | RF | MP NP | P14141 | 60 | 5 | 30 |
|  | a | Qpril 5  | AF | MP NP | P14141 | 60 | 5 | 30 |

**[312] Schedule 1, Part 1, entry for Quinapril in the form Tablet 10 mg (as hydrochloride)**

*omit:*

|  |   |               |    |       |        |    |   |    |
|--|---|---------------|----|-------|--------|----|---|----|
|  | a | Accupril      | PF | MP NP | P14141 | 60 | 5 | 30 |
|  | a | ACQUIN        | RF | MP NP | P14141 | 60 | 5 | 30 |
|  | a | APO-Quinapril | TX | MP NP | P14141 | 60 | 5 | 30 |
|  | a | Qpril 10      | AF | MP NP | P14141 | 60 | 5 | 30 |

**[313] Schedule 1, Part 1, entry for Quinapril in the form Tablet 20 mg (as hydrochloride)**

*omit:*

|  |   |          |    |       |        |    |   |    |
|--|---|----------|----|-------|--------|----|---|----|
|  | a | Accupril | PF | MP NP | P14141 | 60 | 5 | 30 |
|--|---|----------|----|-------|--------|----|---|----|

---

|   |               |    |       |        |    |   |    |
|---|---------------|----|-------|--------|----|---|----|
| a | ACQUIN        | RF | MP NP | P14141 | 60 | 5 | 30 |
| a | APO-Quinapril | TX | MP NP | P14141 | 60 | 5 | 30 |
| a | Qpril 20      | AF | MP NP | P14141 | 60 | 5 | 30 |

**[314] Schedule 1, Part 1, entry for Raloxifene in the form Tablet containing raloxifene hydrochloride 60 mg [Maximum Quantity: 28; Number of Repeats: 5]**

(a) omit from the column headed "Circumstances" (all instances): **C14101**

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14274**

**[315] Schedule 1, Part 1, entry for Raloxifene in the form Tablet containing raloxifene hydrochloride 60 mg [Maximum Quantity: 56; Number of Repeats: 5]**

(a) omit from the column headed "Circumstances" (all instances): **C14101**

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14274**

(c) omit from the column headed "Purposes" (all instances): **P14101** substitute (all instances): **P14274**

**[316] Schedule 1, Part 1, entry for Ramipril in the form Capsule 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[317] Schedule 1, Part 1, entry for Ramipril in the form Capsule 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[318] Schedule 1, Part 1, entry for Ramipril in the form Capsule 5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[319] Schedule 1, Part 1, entry for Ramipril in the form Capsule 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[320] Schedule 1, Part 1, entry for Ramipril in the form Tablet 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[321] Schedule 1, Part 1, entry for Ramipril in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

- 
- [322] **Schedule 1, Part 1, entry for Ramipril in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [323] **Schedule 1, Part 1, entry for Ramipril in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [324] **Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 2.5 mg-2.5 mg (modified release) [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*
- [325] **Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 2.5 mg-2.5 mg (modified release) [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*  
(c) *omit from the column headed "Purposes": P14049* *substitute: P14245*
- [326] **Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 5 mg-5 mg (modified release) [Maximum Quantity: 30; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*
- [327] **Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 5 mg-5 mg (modified release) [Maximum Quantity: 60; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14049*  
(b) *insert in numerical order in the column headed "Circumstances": C14245*  
(c) *omit from the column headed "Purposes": P14049* *substitute: P14245*
- [328] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 5 mg [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14027 C14028 C14089*
-

- 
- (b) *insert in numerical order in the column headed "Circumstances": C14234 C14235 C14263*
- [329] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14027 C14028 C14089*
- (b) *insert in numerical order in the column headed "Circumstances": C14234 C14235 C14263*
- (c) *omit from the column headed "Purposes": P14027 P14028 P14089* *substitute: P14234 P14235 P14263*
- [330] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet (enteric coated) containing risedronate sodium 35 mg [Maximum Quantity: 4; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14027 C14028 C14089*
- (b) *insert in numerical order in the column headed "Circumstances": C14234 C14235 C14263*
- [331] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet (enteric coated) containing risedronate sodium 35 mg [Maximum Quantity: 8; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14027 C14028 C14089*
- (b) *insert in numerical order in the column headed "Circumstances": C14234 C14235 C14263*
- (c) *omit from the column headed "Purposes": P14027 P14028 P14089* *substitute: P14234 P14235 P14263*
- [332] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 35 mg [Maximum Quantity: 4; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14027 C14028 C14089*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14234 C14235 C14263*
- [333] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 35 mg [Maximum Quantity: 8; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14027 C14028 C14089*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14234 C14235 C14263*
- (c) *omit from the column headed "Purposes" (all instances): P14027 P14028 P14089* *substitute (all instances): P14234 P14235 P14263*
-

- 
- [334] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 150 mg [Maximum Quantity: 1; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances):* **C14027 C14028 C14089**
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14234 C14235 C14263**
- [335] **Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 150 mg [Maximum Quantity: 2; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances):* **C14027 C14028 C14089**
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances):* **C14234 C14235 C14263**
  - (c) *omit from the column headed "Purposes" (all instances):* **P14027 P14028 P14089** *substitute (all instances):* **P14234 P14235 P14263**
- [336] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: MP; Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14075 C14116**
  - (b) *insert in numerical order in the column headed "Circumstances":* **C14298**
- [337] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: NP; Maximum Quantity: 60; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14075**
  - (b) *insert in numerical order in the column headed "Circumstances":* **C14298**
- [338] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: MP; Maximum Quantity: 120; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14075 C14116**
  - (b) *insert in numerical order in the column headed "Circumstances":* **C14298**
  - (c) *omit from the column headed "Purposes":* **P14075 P14116** *substitute:* **P14298**
- [339] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: NP; Maximum Quantity: 120; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances":* **C14075**
  - (b) *insert in numerical order in the column headed "Circumstances":* **C14298**
-

- 
- (c) omit from the column headed "Purposes": **P14075** substitute: **P14298**
- [340] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 15; Number of Repeats: 0]**
- (a) omit from the column headed "Circumstances": **C14139**
- (b) insert in numerical order in the column headed "Circumstances": **C14300**
- [341] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 15; Number of Repeats: 1]**
- (a) omit from the column headed "Circumstances": **C14139**
- (b) insert in numerical order in the column headed "Circumstances": **C14300**
- [342] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 30; Number of Repeats: 0]**
- (a) omit from the column headed "Circumstances": **C14139**
- (b) insert in numerical order in the column headed "Circumstances": **C14300**
- [343] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 30; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14139**
- (b) insert in numerical order in the column headed "Circumstances": **C14300**
- [344] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14139**
- (b) insert in numerical order in the column headed "Circumstances": **C14300**
- (c) omit from the column headed "Purposes": **P14139** substitute: **P14300**
- [345] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 15 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances": **C14059**
- (b) insert in numerical order in the column headed "Circumstances": **C14301**
- [346] **Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 15 mg [Maximum Quantity: 42; Number of Repeats: 0]**
- (a) omit from the column headed "Circumstances": **C14059**
- (b) insert in numerical order in the column headed "Circumstances": **C14301**
-

---

**[347] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 15 mg [Maximum Quantity: 56; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances": **C14059**

**(b)** insert in numerical order in the column headed "Circumstances": **C14301**

**(c)** omit from the column headed "Purposes": **P14059** substitute: **P14301**

**[348] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 20 mg [Maximum Quantity: 28; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances": **C14059 C14095 C14139 C14140**

**(b)** insert in numerical order in the column headed "Circumstances": **C14264 C14300 C14301 C14318**

**[349] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 20 mg [Maximum Quantity: 56; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances": **C14059 C14095 C14139 C14140**

**(b)** insert in numerical order in the column headed "Circumstances": **C14264 C14300 C14301 C14318**

**(c)** omit from the column headed "Purposes": **P14059 P14095 P14139 P14140** substitute: **P14264 P14300 P14301 P14318**

**[350] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 5 mg (as calcium)**

*omit:*

|   |                                    |    |    |       |    |    |    |
|---|------------------------------------|----|----|-------|----|----|----|
| a | APX-Rosuvastatin                   | TY | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist<br>Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Cavstat                            | AF | MP | P7598 | 30 | 11 | 30 |
| a | Crestor                            | FK | MP | P7598 | 30 | 11 | 30 |
| a | Crosuva 5                          | RW | MP | P7598 | 30 | 11 | 30 |
| a | Noumed<br>Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor<br>Rosuvastatin 5        | CR | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin<br>APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |

|   |                     |    |    |       |    |    |    |
|---|---------------------|----|----|-------|----|----|----|
| a | Rosuvastatin Lupin  | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin RBX    | RA | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |

**[351] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 5 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**(b)** insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                     |    |       |        |    |   |    |
|---|---------------------|----|-------|--------|----|---|----|
| a | Blooms Rosuvastatin | BG | MP NP | P14238 | 60 | 5 | 30 |
|---|---------------------|----|-------|--------|----|---|----|

**[352] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 10 mg (as calcium)**

omit:

|   |                                 |    |    |       |    |    |    |
|---|---------------------------------|----|----|-------|----|----|----|
| a | APX-Rosuvastatin                | TY | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Cavstat                         | AF | MP | P7598 | 30 | 11 | 30 |
| a | Crestor                         | FK | MP | P7598 | 30 | 11 | 30 |
| a | Crosuva 10                      | RW | MP | P7598 | 30 | 11 | 30 |
| a | Noumed Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor Rosuvastatin 10       | CR | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin Lupin              | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin RBX                | RA | MP | P7598 | 30 | 11 | 30 |

|   |                        |    |    |       |    |    |    |
|---|------------------------|----|----|-------|----|----|----|
| a | Rosuvastatin<br>Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |
|---|------------------------|----|----|-------|----|----|----|

**[353] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 10 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**(b)** insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                        |    |       |        |    |   |    |
|---|------------------------|----|-------|--------|----|---|----|
| a | Blooms<br>Rosuvastatin | BG | MP NP | P14238 | 60 | 5 | 30 |
|---|------------------------|----|-------|--------|----|---|----|

**[354] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 20 mg (as calcium)**

omit:

|   |                                    |    |    |       |    |    |    |
|---|------------------------------------|----|----|-------|----|----|----|
| a | APX-Rosuvastatin                   | TY | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist<br>Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Cavstat                            | AF | MP | P7598 | 30 | 11 | 30 |
| a | Crestor                            | FK | MP | P7598 | 30 | 11 | 30 |
| a | Crosuva 20                         | RW | MP | P7598 | 30 | 11 | 30 |
| a | Noumed<br>Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor<br>Rosuvastatin 20       | CR | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin<br>APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin Lupin                 | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin RBX                   | RA | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin<br>Sandoz             | SZ | MP | P7598 | 30 | 11 | 30 |

**[355] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 20 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**(b)** insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

|   |                        |    |    |    |        |    |   |    |
|---|------------------------|----|----|----|--------|----|---|----|
| a | Blooms<br>Rosuvastatin | BG | MP | NP | P14238 | 60 | 5 | 30 |
|---|------------------------|----|----|----|--------|----|---|----|

**[356] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 40 mg (as calcium)**

omit:

|   |                                    |    |    |       |    |    |    |
|---|------------------------------------|----|----|-------|----|----|----|
| a | APX-Rosuvastatin                   | TY | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist<br>Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Cavstat                            | AF | MP | P7598 | 30 | 11 | 30 |
| a | Crestor                            | FK | MP | P7598 | 30 | 11 | 30 |
| a | Crosuva 40                         | RW | MP | P7598 | 30 | 11 | 30 |
| a | Noumed<br>Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor<br>Rosuvastatin 40       | CR | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin<br>APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin Lupin                 | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin RBX                   | RA | MP | P7598 | 30 | 11 | 30 |
| a | Rosuvastatin<br>Sandoz             | SZ | MP | P7598 | 30 | 11 | 30 |

**[357] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 40 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]**

**(a)** omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**(b)** insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

|  |   |                        |    |    |    |        |    |   |    |
|--|---|------------------------|----|----|----|--------|----|---|----|
|  | a | Blooms<br>Rosuvastatin | BG | MP | NP | P14238 | 60 | 5 | 30 |
|--|---|------------------------|----|----|----|--------|----|---|----|

- [358] **Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14051*
- (b) *insert in numerical order in the column headed "Circumstances": C14254*
- [359] **Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg [Maximum Quantity: 112; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14051*
- (b) *insert in numerical order in the column headed "Circumstances": C14254*
- (c) *omit from the column headed "Purposes": P14051 substitute: P14254*
- [360] **Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14051*
- (b) *insert in numerical order in the column headed "Circumstances": C14254*
- [361] **Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg [Maximum Quantity: 112; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14051*
- (b) *insert in numerical order in the column headed "Circumstances": C14254*
- (c) *omit from the column headed "Purposes": P14051 substitute: P14254*
- [362] **Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14051*
- (b) *insert in numerical order in the column headed "Circumstances": C14254*

---

**[363] Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg [Maximum Quantity: 112; Number of Repeats: 5]**

**(a)** omit from the column headed "Circumstances": **C14051**

**(b)** insert in numerical order in the column headed "Circumstances": **C14254**

**(c)** omit from the column headed "Purposes": **P14051** substitute: **P14254**

**[364] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 5 mg**

omit:

|   |                    |    |    |       |    |    |    |
|---|--------------------|----|----|-------|----|----|----|
| a | Simvastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |
| a | Zimstat            | AF | MP | P7598 | 30 | 11 | 30 |

**[365] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[366] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 10 mg**

omit:

|   |                       |    |    |       |    |    |    |
|---|-----------------------|----|----|-------|----|----|----|
| a | APO-Simvastatin       | TX | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED<br>SIMVASTATIN | VO | MP | P7598 | 30 | 11 | 30 |
| a | Simvar 10             | RW | MP | P7598 | 30 | 11 | 30 |
| a | Simvastatin Sandoz    | SZ | MP | P7598 | 30 | 11 | 30 |
| a | Zimstat               | AF | MP | P7598 | 30 | 11 | 30 |

**[367] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[368] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 20 mg**

omit:

|   |                 |    |    |       |    |    |    |
|---|-----------------|----|----|-------|----|----|----|
| a | APO-Simvastatin | TX | MP | P7598 | 30 | 11 | 30 |
|---|-----------------|----|----|-------|----|----|----|

|   |                       |    |    |       |    |    |    |
|---|-----------------------|----|----|-------|----|----|----|
| a | Lipex 20              | AL | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED<br>SIMVASTATIN | VO | MP | P7598 | 30 | 11 | 30 |
| a | Simvar 20             | RW | MP | P7598 | 30 | 11 | 30 |
| a | Simvastatin Sandoz    | SZ | MP | P7598 | 30 | 11 | 30 |
| a | Zimstat               | AF | MP | P7598 | 30 | 11 | 30 |
| a | Zocor                 | MQ | MP | P7598 | 30 | 11 | 30 |

**[369] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 20 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141*

*substitute (all instances): P14238*

**[370] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 40 mg**

*omit:*

|   |                       |    |    |       |    |    |    |
|---|-----------------------|----|----|-------|----|----|----|
| a | APO-Simvastatin       | TX | MP | P7598 | 30 | 11 | 30 |
| a | Lipex 40              | AL | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED<br>SIMVASTATIN | VO | MP | P7598 | 30 | 11 | 30 |
| a | Simvar 40             | RW | MP | P7598 | 30 | 11 | 30 |
| a | Simvastatin Sandoz    | SZ | MP | P7598 | 30 | 11 | 30 |
| a | Zimstat               | AF | MP | P7598 | 30 | 11 | 30 |
| a | Zocor                 | MQ | MP | P7598 | 30 | 11 | 30 |

**[371] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 40 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141*

*substitute (all instances): P14238*

**[372] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 80 mg**

*omit:*

|   |                    |    |    |       |    |    |    |
|---|--------------------|----|----|-------|----|----|----|
| a | APO-Simvastatin    | TX | MP | P7598 | 30 | 11 | 30 |
| a | Simvar 80          | RW | MP | P7598 | 30 | 11 | 30 |
| a | Simvastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |
| a | Zimstat            | AF | MP | P7598 | 30 | 11 | 30 |

**[373] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 80 mg [Maximum Quantity: 60; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[374] Schedule 1, Part 1, entry for Spironolactone in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[375] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg**

*omit:*

|  |  |  |    |       |     |    |     |
|--|--|--|----|-------|-----|----|-----|
|  |  |  | MP | P4894 | 200 | 11 | 100 |
|--|--|--|----|-------|-----|----|-----|

**[376] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg [Maximum Quantity: 400; Number of Repeats: 5]**

*omit from the column headed "Purposes": P14141 substitute: P14238*

**[377] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg (enteric coated)**

*omit:*

|   |                |    |    |       |     |    |     |
|---|----------------|----|----|-------|-----|----|-----|
| a | Pyralin EN     | FZ | MP | P4894 | 200 | 11 | 100 |
| a | Salazopyrin-EN | PF | MP | P4894 | 200 | 11 | 100 |

**[378] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 400; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[379] Schedule 1, Part 1, entry for Telmisartan in the form Tablet 40 mg [Maximum Quantity: 56; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

**[380] Schedule 1, Part 1, entry for Telmisartan in the form Tablet 80 mg [Maximum Quantity: 56; Number of Repeats: 5]**

*omit from the column headed "Purposes" (all instances): P14141 substitute (all instances): P14238*

- 
- [381] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-5 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- [382] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-5 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
  - (c) *omit from the column headed "Purposes" (all instances): P14043*      *substitute (all instances): P14257*
- [383] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-10 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- [384] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-10 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
  - (c) *omit from the column headed "Purposes" (all instances): P14043*      *substitute (all instances): P14257*
- [385] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-5 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
- [386] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-5 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14043*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14257*
-

- 
- (c) omit from the column headed "Purposes" (all instances): **P14043** substitute (all instances): **P14257**
- [387] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-10 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14043**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14257**
- [388] **Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-10 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14043**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14257**
- (c) omit from the column headed "Purposes" (all instances): **P14043** substitute (all instances): **P14257**
- [389] **Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 40 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**
- [390] **Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 40 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**
- (c) omit from the column headed "Purposes" (all instances): **P14061** substitute (all instances): **P14255**
- [391] **Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14061**
- (b) insert in numerical order in the column headed "Circumstances" (all instances): **C14255**
- [392] **Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) omit from the column headed "Circumstances" (all instances): **C14061**
-

- 
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- (c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [393] **Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14061*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [394] **Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14061*
- (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- (c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [395] **Schedule 1, Part 1, entry for Thiamine in the form Tablet containing thiamine hydrochloride 100 mg [Maximum Quantity: 100; Number of Repeats: 2]**
- (a) *omit from the column headed "Circumstances": C14020*
- (b) *insert in numerical order in the column headed "Circumstances": C14319*
- [396] **Schedule 1, Part 1, entry for Thiamine in the form Tablet containing thiamine hydrochloride 100 mg [Maximum Quantity: 200; Number of Repeats: 2]**
- (a) *omit from the column headed "Circumstances": C14020*
- (b) *insert in numerical order in the column headed "Circumstances": C14319*
- (c) *omit from the column headed "Purposes": P14020*      *substitute: P14319*
- [397] **Schedule 1, Part 1, entry for Ticagrelor in the form Tablet 90 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14076*
- (b) *insert in numerical order in the column headed "Circumstances": C14240*
- [398] **Schedule 1, Part 1, entry for Ticagrelor in the form Tablet 90 mg [Maximum Quantity: 112; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances": C14076*
-

- 
- (b) *insert in numerical order in the column headed "Circumstances":* **C14240**
- (c) *omit from the column headed "Purposes":* **P14076** *substitute:* **P14240**
- [399] **Schedule 1, Part 1, entry for Trandolapril in the form Capsule 500 micrograms [Maximum Quantity: 56; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances):* **P14141** *substitute (all instances):* **P14238**
- [400] **Schedule 1, Part 1, entry for Trandolapril in the form Capsule 1 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances):* **P14141** *substitute (all instances):* **P14238**
- [401] **Schedule 1, Part 1, entry for Trandolapril in the form Capsule 2 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances):* **P14141** *substitute (all instances):* **P14238**
- [402] **Schedule 1, Part 1, entry for Trandolapril in the form Capsule 4 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances):* **P14141** *substitute (all instances):* **P14238**
- [403] **Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances":* **C14119**  
(b) *insert in numerical order in the column headed "Circumstances":* **C14244**
- [404] **Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) [Maximum Quantity: 56; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances":* **C14119**  
(b) *insert in numerical order in the column headed "Circumstances":* **C14244**  
(c) *omit from the column headed "Purposes":* **P14119** *substitute:* **P14244**
- [405] **Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances":* **C14119**  
(b) *insert in numerical order in the column headed "Circumstances":* **C14244**
-

- 
- [406] **Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) [Maximum Quantity: 56; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances": C14119*  
(b) *insert in numerical order in the column headed "Circumstances": C14244*  
(c) *omit from the column headed "Purposes": P14119* *substitute: P14244*
- [407] **Schedule 1, Part 1, entry for Valsartan in the form Tablet 80 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [408] **Schedule 1, Part 1, entry for Valsartan in the form Tablet 160 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [409] **Schedule 1, Part 1, entry for Valsartan in the form Tablet 320 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
*omit from the column headed "Purposes" (all instances): P14141* *substitute (all instances): P14238*
- [410] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [411] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*  
(c) *omit from the column headed "Purposes" (all instances): P14061* *substitute (all instances): P14255*
- [412] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]**  
(a) *omit from the column headed "Circumstances" (all instances): C14061*  
(b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
-

- 
- [413] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14061*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
  - (c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [414] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14061*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
- [415] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14061*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14255*
  - (c) *omit from the column headed "Purposes" (all instances): P14061*      *substitute (all instances): P14255*
- [416] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14108*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14311*
- [417] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14108*
  - (b) *insert in numerical order in the column headed "Circumstances" (all instances): C14311*
  - (c) *omit from the column headed "Purposes" (all instances): P14108*      *substitute (all instances): P14311*
- [418] **Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]**
- (a) *omit from the column headed "Circumstances" (all instances): C14108*
-

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14311**

**[419] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]**

(a) omit from the column headed "Circumstances" (all instances): **C14108**

(b) insert in numerical order in the column headed "Circumstances" (all instances): **C14311**

(c) omit from the column headed "Purposes" (all instances): **P14108** substitute (all instances): **P14311**

**[420] Schedule 1, Part 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 80 mg [Maximum Quantity: 200; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[421] Schedule 1, Part 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 180 mg (sustained release) [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[422] Schedule 1, Part 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 240 mg (sustained release) [Maximum Quantity: 60; Number of Repeats: 5]**

omit from the column headed "Purposes" (all instances): **P14141** substitute (all instances): **P14238**

**[423] Schedule 1, Part 2, after entry for Amino acid formula with vitamins and minerals without phenylalanine**

insert:

|              |                           |      |   |                                 |    |    |       |    |    |    |
|--------------|---------------------------|------|---|---------------------------------|----|----|-------|----|----|----|
| Atorvastatin | Tablet 10 mg (as calcium) | Oral | a | APO-Atorvastatin                | TX | MP | P7598 | 30 | 11 | 30 |
|              |                           |      | a | Atorvachol                      | RF | MP | P7598 | 30 | 11 | 30 |
|              |                           |      | a | Atorvastatin GH                 | GQ | MP | P7598 | 30 | 11 | 30 |
|              |                           |      | a | Atorvastatin SZ                 | HX | MP | P7598 | 30 | 11 | 30 |
|              |                           |      | a | Blooms the Chemist Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|              |                           |      | a | Lipitor                         | AS | MP | P7598 | 30 | 11 | 30 |
|              |                           |      | a | Lorstat 10                      | AF | MP | P7598 | 30 | 11 | 30 |

|                           |      |   |                                    |    |    |       |    |    |    |
|---------------------------|------|---|------------------------------------|----|----|-------|----|----|----|
| Tablet 20 mg (as calcium) | Oral | a | NOUMED<br>ATORVASTATIN             | VO | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Pharmacor<br>Atorvastatin          | CR | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Trovas                             | RA | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | APO-Atorvastatin                   | TX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvachol                         | RF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvastatin GH                    | GQ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvastatin SZ                    | HX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Blooms the Chemist<br>Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Lipitor                            | AS | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Lorstat 20                         | AF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | NOUMED<br>ATORVASTATIN             | VO | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Pharmacor<br>Atorvastatin          | CR | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Trovas                             | RA | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | APO-Atorvastatin                   | TX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvachol                         | RF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvastatin GH                    | GQ | MP | P7598 | 30 | 11 | 30 |
| Tablet 40 mg (as calcium) | Oral | a | Atorvastatin SZ                    | HX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Blooms the Chemist<br>Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Lipitor                            | AS | MP | P7598 | 30 | 11 | 30 |

|                           |      |   |                                    |    |    |       |    |    |    |
|---------------------------|------|---|------------------------------------|----|----|-------|----|----|----|
| Tablet 80 mg (as calcium) | Oral | a | Lorstat 40                         | AF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | NOUMED<br>ATORVASTATIN             | VO | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Pharmacor<br>Atorvastatin          | CR | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Trovas                             | RA | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | APO-Atorvastatin                   | TX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvachol                         | RF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvastatin GH                    | GQ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Atorvastatin SZ                    | HX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Blooms the Chemist<br>Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Lipitor                            | AS | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Lorstat 80                         | AF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | NOUMED<br>ATORVASTATIN             | VO | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Pharmacor<br>Atorvastatin          | CR | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Trovas                             | RA | MP | P7598 | 30 | 11 | 30 |

**[424] Schedule 1, Part 2, after entry for Ertugliflozin with sitagliptin in the form Tablet containing 15 mg ertugliflozin with 100 mg sitagliptin**

*insert:*

|             |              |      |   |                   |    |    |       |    |    |    |
|-------------|--------------|------|---|-------------------|----|----|-------|----|----|----|
| Fenofibrate | Tablet 48 mg | Oral | a | APO-Fenofibrate   | TX | MP | P7640 | 60 | 11 | 60 |
|             |              |      | a | Fenofibrate Cipla | LR | MP | P7640 | 60 | 11 | 60 |
|             |              |      | a | Fenofibrate Mylan | AF | MP | P7640 | 60 | 11 | 60 |
|             |              |      | a | FENOFIBRATE       | RA | MP | P7640 | 60 | 11 | 60 |

|             |               |      |                                              |                                |           |    |       |       |    |    |
|-------------|---------------|------|----------------------------------------------|--------------------------------|-----------|----|-------|-------|----|----|
|             |               |      | RBX                                          |                                |           |    |       |       |    |    |
| Fluvastatin | Tablet 145 mg | Oral | a                                            | Fenofibrate Viatris            | AL        | MP | P7640 | 60    | 11 | 60 |
|             |               |      | a                                            | Lipidil                        | GO        | MP | P7640 | 60    | 11 | 60 |
|             |               |      | a                                            | APO-Fenofibrate                | TX        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | Blooms the Chemist Fenofibrate | IB        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | Fenocol                        | YC        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | Fenofibrate Cipla              | LR        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | Fenofibrate Mylan              | AF        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | FENOFIBRATE RBX                | RA        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | Fenofibrate Sandoz             | SZ        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | Fenofibrate Viatris            | AL        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | a                                            | Lipidil                        | GO        | MP | P7640 | 30    | 11 | 30 |
|             |               |      | Tablet (prolonged release) 80 mg (as sodium) | Oral                           | Lescol XL | NV | MP    | P7598 | 28 | 11 |

**[425] Schedule 1, Part 2, after entry for Galantamine in the form Capsule (prolonged release) 24 mg (as hydrobromide)**

*insert:*

|             |               |      |   |         |    |    |       |    |    |    |
|-------------|---------------|------|---|---------|----|----|-------|----|----|----|
| Gemfibrozil | Tablet 600 mg | Oral | a | Ausgem  | RW | MP | P7640 | 60 | 11 | 60 |
|             |               |      | a | Lipigem | AF | MP | P7640 | 60 | 11 | 60 |

**[426] Schedule 1, Part 2, after entry for Norethisterone with mestranol**

*insert:*

|                    |                                                                                        |      |  |              |    |    |       |     |    |     |
|--------------------|----------------------------------------------------------------------------------------|------|--|--------------|----|----|-------|-----|----|-----|
| Pancreatic extract | Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP | Oral |  | Creon 10,000 | GO | MP | P5779 | 500 | 21 | 100 |
|--------------------|----------------------------------------------------------------------------------------|------|--|--------------|----|----|-------|-----|----|-----|

|  |                                                                                                                 |      |              |    |    |       |     |    |     |
|--|-----------------------------------------------------------------------------------------------------------------|------|--------------|----|----|-------|-----|----|-----|
|  | units of lipase activity                                                                                        |      |              |    |    |       |     |    |     |
|  | Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | Oral | Creon 25,000 | GO | MP | P5779 | 200 | 21 | 100 |
|  | Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity | Oral | Creon 35,000 | GO | MP | P5779 | 200 | 21 | 100 |
|  | Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g            | Oral | Creon Micro  | GO | MP | P5779 | 3   | 21 | 1   |

**[427] Schedule 1, Part 2, after entry for Polyvinyl alcohol**

*insert:*

|             |                                            |      |   |                    |    |    |       |    |    |    |
|-------------|--------------------------------------------|------|---|--------------------|----|----|-------|----|----|----|
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | a | APO-Pravastatin    | TX | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | APX-Pravastatin    | TY | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Cholstat 10        | AF | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Lipostat 10        | RF | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Pravachol          | RW | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Pravastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |
|             | Tablet containing pravastatin sodium 20 mg | Oral | a | APO-Pravastatin    | TX | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | APX-Pravastatin    | TY | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Cholstat 20        | AF | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Lipostat 20        | RF | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Pravachol          | RW | MP | P7598 | 30 | 11 | 30 |
|             |                                            |      | a | Pravastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |

|                                            |      |   |                    |    |    |       |    |    |    |
|--------------------------------------------|------|---|--------------------|----|----|-------|----|----|----|
| Tablet containing pravastatin sodium 40 mg | Oral | a | Pravastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | APO-Pravastatin    | TX | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | APX-Pravastatin    | TY | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | Cholstat 40        | AF | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | Lipostat 40        | RF | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | Pravachol          | RW | MP | P7598 | 30 | 11 | 30 |
| Tablet containing pravastatin sodium 80 mg | Oral | a | Pravastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | APO-Pravastatin    | TX | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | APX-Pravastatin    | TY | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | Lipostat 80        | RF | MP | P7598 | 30 | 11 | 30 |
|                                            |      | a | Pravachol          | RW | MP | P7598 | 30 | 11 | 30 |
|                                            |      |   |                    |    |    |       |    |    |    |

**[428] Schedule 1, Part 2, after entry for Rivastigmine in the form Transdermal patch 27 mg**

*insert:*

|              |                          |      |   |                                    |    |    |       |    |    |    |
|--------------|--------------------------|------|---|------------------------------------|----|----|-------|----|----|----|
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | a | APX-Rosuvastatin                   | TY | MP | P7598 | 30 | 11 | 30 |
|              |                          |      | a | Blooms the Chemist<br>Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|              |                          |      | a | Cavstat                            | AF | MP | P7598 | 30 | 11 | 30 |
|              |                          |      | a | Crestor                            | FK | MP | P7598 | 30 | 11 | 30 |
|              |                          |      | a | Crosuva 5                          | RW | MP | P7598 | 30 | 11 | 30 |
|              |                          |      | a | Noumed<br>Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
|              |                          |      | a | Pharmacor<br>Rosuvastatin 5        | CR | MP | P7598 | 30 | 11 | 30 |

|                           |      |   |                                    |    |    |       |    |    |    |
|---------------------------|------|---|------------------------------------|----|----|-------|----|----|----|
| Tablet 10 mg (as calcium) | Oral | a | Rosuvastatin<br>APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin Lupin                 | GQ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin RBX                   | RA | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin<br>Sandoz             | SZ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | APX-Rosuvastatin                   | TY | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Blooms the Chemist<br>Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Cavstat                            | AF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Crestor                            | FK | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Crosuva 10                         | RW | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Noumed<br>Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Pharmacor<br>Rosuvastatin 10       | CR | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin<br>APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin Lupin                 | GQ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin RBX                   | RA | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin<br>Sandoz             | SZ | MP | P7598 | 30 | 11 | 30 |
| Tablet 20 mg (as calcium) | Oral | a | APX-Rosuvastatin                   | TY | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Blooms the Chemist<br>Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Cavstat                            | AF | MP | P7598 | 30 | 11 | 30 |

|                           |      |   |                                    |    |    |       |    |    |    |
|---------------------------|------|---|------------------------------------|----|----|-------|----|----|----|
| Tablet 40 mg (as calcium) | Oral | a | Crestor                            | FK | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Crosuva 20                         | RW | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Noumed<br>Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Pharmacor<br>Rosuvastatin 20       | CR | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin<br>APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin Lupin                 | GQ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin RBX                   | RA | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin<br>Sandoz             | SZ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | APX-Rosuvastatin                   | TY | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Blooms the Chemist<br>Rosuvastatin | IB | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Cavstat                            | AF | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Crestor                            | FK | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Crosuva 40                         | RW | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Noumed<br>Rosuvastatin             | VO | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Pharmacor<br>Rosuvastatin 40       | CR | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin<br>APOTEX             | GX | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin Lupin                 | GQ | MP | P7598 | 30 | 11 | 30 |
|                           |      | a | Rosuvastatin RBX                   | RA | MP | P7598 | 30 | 11 | 30 |

|             |              |      |   |                     |    |    |       |    |    |    |
|-------------|--------------|------|---|---------------------|----|----|-------|----|----|----|
| Simvastatin | Tablet 5 mg  | Oral | a | Rosuvastatin Sandoz | SZ | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Simvastatin Sandoz  | SZ | MP | P7598 | 30 | 11 | 30 |
|             |              | Oral | a | Zimstat             | AF | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | APO-Simvastatin     | TX | MP | P7598 | 30 | 11 | 30 |
|             | Tablet 10 mg | Oral | a | NOUMED SIMVASTATIN  | VO | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Simvar 10           | RW | MP | P7598 | 30 | 11 | 30 |
|             |              | Oral | a | Simvastatin Sandoz  | SZ | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Zimstat             | AF | MP | P7598 | 30 | 11 | 30 |
|             | Tablet 20 mg | Oral | a | APO-Simvastatin     | TX | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Lipex 20            | AL | MP | P7598 | 30 | 11 | 30 |
|             |              | Oral | a | NOUMED SIMVASTATIN  | VO | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Simvar 20           | RW | MP | P7598 | 30 | 11 | 30 |
|             | Tablet 40 mg | Oral | a | Simvastatin Sandoz  | SZ | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Zimstat             | AF | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Zocor               | MQ | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | APO-Simvastatin     | TX | MP | P7598 | 30 | 11 | 30 |
|             |              | Oral | a | Lipex 40            | AL | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | NOUMED SIMVASTATIN  | VO | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Simvar 40           | RW | MP | P7598 | 30 | 11 | 30 |
|             |              |      | a | Simvastatin Sandoz  | SZ | MP | P7598 | 30 | 11 | 30 |

|               |                                |      |   |                    |    |    |       |     |    |     |
|---------------|--------------------------------|------|---|--------------------|----|----|-------|-----|----|-----|
|               |                                |      | a | Zimstat            | AF | MP | P7598 | 30  | 11 | 30  |
|               |                                |      | a | Zocor              | MQ | MP | P7598 | 30  | 11 | 30  |
|               | Tablet 80 mg                   | Oral | a | APO-Simvastatin    | TX | MP | P7598 | 30  | 11 | 30  |
|               |                                |      | a | Simvar 80          | RW | MP | P7598 | 30  | 11 | 30  |
|               |                                |      | a | Simvastatin Sandoz | SZ | MP | P7598 | 30  | 11 | 30  |
|               |                                |      | a | Zimstat            | AF | MP | P7598 | 30  | 11 | 30  |
| Sulfasalazine | Tablet 500 mg                  | Oral |   | Salazopyrin        | PF | MP | P4894 | 200 | 11 | 100 |
|               | Tablet 500 mg (enteric coated) | Oral | a | Pyralin EN         | FZ | MP | P4894 | 200 | 11 | 100 |
|               |                                |      | a | Salazopyrin-EN     | PF | MP | P4894 | 200 | 11 | 100 |

**[429] Schedule 4, Part 1, entry for Adapalene with benzoyl peroxide [Circumstances Code: C14133]**

(a) omit from the column headed "Circumstances Code": **C14133** substitute: **C14275**

(b) omit from the column headed "Purposes Code": **P14133** substitute: **P14275**

**[430] Schedule 4, Part 1, entry for Alendronic acid [Circumstances Code: C14027]**

(a) omit from the column headed "Circumstances Code": **C14027** substitute: **C14291**

(b) omit from the column headed "Purposes Code": **P14027** substitute: **P14291**

**[431] Schedule 4, Part 1, entry for Alendronic acid [Circumstances Code: C14028]**

(a) omit from the column headed "Circumstances Code": **C14028** substitute: **C14242**

(b) omit from the column headed "Purposes Code": **P14028** substitute: **P14242**

**[432] Schedule 4, Part 1, entry for Alendronic acid [Circumstances Code: C14089]**

(a) omit from the column headed "Circumstances Code": **C14089** substitute: **C14309**

(b) omit from the column headed "Purposes Code": **P14089** substitute: **P14309**

**[433] Schedule 4, Part 1, entry for Allopurinol**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

- 
- [434] **Schedule 4, Part 1, entry for Amlodipine**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [435] **Schedule 4, Part 1, entry for Amlodipine with atorvastatin**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [436] **Schedule 4, Part 1, entry for Amlodipine with valsartan [Circumstances Code: C14043]**  
(a) *omit from the column headed "Circumstances Code": C14043* *substitute: C14257*  
(b) *omit from the column headed "Purposes Code": P14043* *substitute: P14257*
- [437] **Schedule 4, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide [Circumstances Code: C14062]**  
(a) *omit from the column headed "Circumstances Code": C14062* *substitute: C14272*  
(b) *omit from the column headed "Purposes Code": P14062* *substitute: P14272*
- [438] **Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14078]**  
(a) *omit from the column headed "Circumstances Code": C14078* *substitute: C14308*  
(b) *omit from the column headed "Purposes Code": P14078* *substitute: P14308*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14078* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14308*
- [439] **Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14095]**  
(a) *omit from the column headed "Circumstances Code": C14095* *substitute: C14264*  
(b) *omit from the column headed "Purposes Code": P14095* *substitute: P14264*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14095* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14264*
- [440] **Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14129]**  
(a) *omit from the column headed "Circumstances Code": C14129* *substitute: C14302*  
(b) *omit from the column headed "Purposes Code": P14129* *substitute: P14302*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14129* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14302*
-

- 
- [441] **Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14139]**  
(a) *omit from the column headed "Circumstances Code": C14139* *substitute: C14300*  
(b) *omit from the column headed "Purposes Code": P14139* *substitute: P14300*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14139* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14300*
- [442] **Schedule 4, Part 1, entry for Atenolol [Circumstances Code: C14039]**  
(a) *omit from the column headed "Circumstances Code": C14039* *substitute: C14305*  
(b) *omit from the column headed "Purposes Code": P14039* *substitute: P14305*
- [443] **Schedule 4, Part 1, entry for Atenolol [Purposes Code: P14141]**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [444] **Schedule 4, Part 1, entry for Atorvastatin [Purposes Code: P14141]**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [445] **Schedule 4, Part 1, entry for Baclofen [Purposes Code: P14141]**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [446] **Schedule 4, Part 1, entry for Balsalazide [Circumstances Code: C14084]**  
(a) *omit from the column headed "Circumstances Code": C14084* *substitute: C14306*  
(b) *omit from the column headed "Purposes Code": P14084* *substitute: P14306*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14084* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14306*
- [447] **Schedule 4, Part 1, entry for Bisoprolol [Circumstances Code: C14033]**  
(a) *omit from the column headed "Circumstances Code": C14033* *substitute: C14251*  
(b) *omit from the column headed "Purposes Code": P14033* *substitute: P14251*
- [448] **Schedule 4, Part 1, entry for Calcipotriol with betamethasone [Circumstances Code: C14091]**  
(a) *omit from the column headed "Circumstances Code": C14091* *substitute: C14236*
-

- 
- (b) omit from the column headed "Purposes Code": **P14091** substitute: **P14236**
- [449] **Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14071]**
- (a) omit from the column headed "Circumstances Code": **C14071** substitute: **C14287**
- (b) omit from the column headed "Purposes Code": **P14071** substitute: **P14287**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14071** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14287**
- [450] **Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14087]**
- (a) omit from the column headed "Circumstances Code": **C14087** substitute: **C14322**
- (b) omit from the column headed "Purposes Code": **P14087** substitute: **P14322**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14087** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14322**
- [451] **Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14088]**
- (a) omit from the column headed "Circumstances Code": **C14088** substitute: **C14296**
- (b) omit from the column headed "Purposes Code": **P14088** substitute: **P14296**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14088** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14296**
- [452] **Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14100]**
- (a) omit from the column headed "Circumstances Code": **C14100** substitute: **C14231**
- (b) omit from the column headed "Purposes Code": **P14100** substitute: **P14231**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14100** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14231**
- [453] **Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14111]**
- (a) omit from the column headed "Circumstances Code": **C14111** substitute: **C14259**
- (b) omit from the column headed "Purposes Code": **P14111** substitute: **P14259**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14111** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14259**
-

- 
- [454] **Schedule 4, Part 1, entry for Calcium [Circumstances Code: C14054]**  
(a) *omit from the column headed "Circumstances Code":* **C14054** *substitute:* **C14228**  
(b) *omit from the column headed "Purposes Code":* **P14054** *substitute:* **P14228**  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)":* **Compliance with Authority Required procedures - Streamlined Authority Code 14054** *substitute:* **Compliance with Authority Required procedures - Streamlined Authority Code 14228**
- [455] **Schedule 4, Part 1, entry for Candesartan**  
*omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [456] **Schedule 4, Part 1, entry for Candesartan with hydrochlorothiazide [Circumstances Code: C14061]**  
(a) *omit from the column headed "Circumstances Code":* **C14061** *substitute:* **C14255**  
(b) *omit from the column headed "Purposes Code":* **P14061** *substitute:* **P14255**
- [457] **Schedule 4, Part 1, entry for Carvedilol [Circumstances Code: C14033]**  
(a) *omit from the column headed "Circumstances Code":* **C14033** *substitute:* **C14251**  
(b) *omit from the column headed "Purposes Code":* **P14033** *substitute:* **P14251**
- [458] **Schedule 4, Part 1, entry for Carvedilol [Circumstances Code: C14115]**  
(a) *omit from the column headed "Circumstances Code":* **C14115** *substitute:* **C14270**  
(b) *omit from the column headed "Purposes Code":* **P14115** *substitute:* **P14270**
- [459] **Schedule 4, Part 1, entry for Chlortalidone**  
*omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [460] **Schedule 4, Part 1, entry for Clonidine**  
*omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [461] **Schedule 4, Part 1, entry for Clopidogrel**  
*omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
-

- 
- [462] **Schedule 4, Part 1, entry for Clopidogrel with aspirin**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [463] **Schedule 4, Part 1, entry for Dabigatran etexilate [Circumstances Code: C14078]**  
(a) *omit from the column headed "Circumstances Code": C14078* *substitute: C14308*  
(b) *omit from the column headed "Purposes Code": P14078* *substitute: P14308*
- [464] **Schedule 4, Part 1, entry for Enalapril**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [465] **Schedule 4, Part 1, entry for Enalapril with hydrochlorothiazide [Circumstances Code: C14107]**  
(a) *omit from the column headed "Circumstances Code": C14107* *substitute: C14280*  
(b) *omit from the column headed "Purposes Code": P14107* *substitute: P14280*
- [466] **Schedule 4, Part 1, entry for Eplerenone [Circumstances Code: C14035]**  
(a) *omit from the column headed "Circumstances Code": C14035* *substitute: C14266*  
(b) *omit from the column headed "Purposes Code": P14035* *substitute: P14266*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14035* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14266*
- [467] **Schedule 4, Part 1, entry for Ezetimibe [Circumstances Code: C14135]**  
(a) *omit from the column headed "Circumstances Code": C14135* *substitute: C14249*  
(b) *omit from the column headed "Purposes Code": P14135* *substitute: P14249*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14135* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14249*
- [468] **Schedule 4, Part 1, entry for Ezetimibe [Circumstances Code: C14136]**  
(a) *omit from the column headed "Circumstances Code": C14136* *substitute: C14283*  
(b) *omit from the column headed "Purposes Code": P14136* *substitute: P14283*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14136* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14283*
-

**[469] Schedule 4, Part 1, entry for Ezetimibe [Circumstances Code: C14137]**

- (a) omit from the column headed "Circumstances Code": **C14137** substitute: **C14310**  
 (b) omit from the column headed "Purposes Code": **P14137** substitute: **P14310**  
 (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14137** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14310**

**[470] Schedule 4, Part 1, entry for Ezetimibe and rosuvastatin [Circumstances Code: C14057]**

- (a) omit from the column headed "Circumstances Code": **C14057** substitute: **C14284**  
 (b) omit from the column headed "Purposes Code": **P14057** substitute: **P14284**  
 (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14057** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14284**

**[471] Schedule 4, Part 1, entry for Ezetimibe and rosuvastatin**

*insert in numerical order after existing text:*

|  |        |        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                         |
|--|--------|--------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|  | C14350 | P14350 |  | <p>Hypercholesterolaemia</p> <p>The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND</p> <p>The treatment must be in conjunction with dietary therapy and exercise; AND</p> <p>Patient must have cholesterol concentrations that are inadequately controlled with an HMG CoA reductase inhibitor (statin); AND</p> <p>Patient must have developed a clinically important product-related adverse event during treatment with an HMG CoA reductase inhibitor (statin) necessitating a reduction in the statin dose; AND</p> <p>Patient must have coronary heart disease; OR</p> <p>Patient must have cerebrovascular disease; OR</p> <p>Patient must have peripheral vascular disease; OR</p> <p>Patient must have diabetes mellitus with microalbuminuria; OR</p> <p>Patient must be an Aboriginal or Torres Strait Islander with diabetes mellitus; OR</p> <p>Patient must have diabetes mellitus and be aged 60 years or more; OR</p> <p>Patient must have a family history of coronary heart disease in two or more first degree relatives before the age of 55 years; OR</p> <p>Patient must have a family history of coronary heart disease in one or more first degree relatives before the age of 45 years; OR</p> <p>Patient must have heterozygous familial hypercholesterolaemia; OR</p> <p>Patient must have homozygous familial hypercholesterolaemia; OR</p> <p>Patient must have a level of absolute risk of a cardiovascular event greater than 15% over 5 years as calculated using the Australian Absolute Cardiovascular Disease Risk Calculator (National Vascular Disease Prevention Alliance), as in force on 1 April 2018.</p> | <p>Compliance with Authority Required procedures - Streamlined Authority Code 14350</p> |
|--|--------|--------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|

|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |  |
|--|--|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|  |  |  |  | <p>A clinically important product-related adverse event is defined as follows:</p> <p>(i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or</p> <p>(ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or</p> <p>(iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.</p> <p>Microalbuminuria is defined as urinary albumin excretion rate of greater than 20mcg/min or urinary albumin to creatinine ratio of greater than 2.5 for males, or greater than 3.5 for females.</p> <p>The type and severity of the adverse event or contraindication must be documented in the patient's medical records.</p> |  |
|--|--|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

**[472] Schedule 4, Part 1, entry for Ezetimibe with atorvastatin [Circumstances Code: C14056]**

- (a) omit from the column headed "Circumstances Code": **C14056** substitute: **C14269**
- (b) omit from the column headed "Purposes Code": **P14056** substitute: **P14269**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14056** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14269**

**[473] Schedule 4, Part 1, entry for Ezetimibe with atorvastatin [Circumstances Code: C14057]**

- (a) omit from the column headed "Circumstances Code": **C14057** substitute: **C14284**
- (b) omit from the column headed "Purposes Code": **P14057** substitute: **P14284**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14057** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14284**

**[474] Schedule 4, Part 1, entry for Ezetimibe with atorvastatin**

*insert in numerical order after existing text:*

|  |        |        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                         |
|--|--------|--------|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|  | C14348 | P14348 |  | <p>Hypercholesterolaemia</p> <p>The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND</p> <p>The treatment must be in conjunction with dietary therapy and exercise; AND</p> <p>Patient must have cholesterol concentrations that are inadequately controlled with an HMG CoA reductase inhibitor (statin); AND</p> <p>Patient must have coronary heart disease; OR</p> <p>Patient must have cerebrovascular disease; OR</p> <p>Patient must have peripheral vascular disease; OR</p> <p>Patient must have diabetes mellitus with microalbuminuria; OR</p> <p>Patient must be an Aboriginal or Torres Strait Islander with diabetes mellitus; OR</p> | <p>Compliance with Authority Required procedures - Streamlined Authority Code 14348</p> |
|--|--------|--------|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|

|  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |  |
|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|  |  |  | <p>Patient must have diabetes mellitus and be aged 60 years or more; OR</p> <p>Patient must have a family history of coronary heart disease in two or more first degree relatives before the age of 55 years; OR</p> <p>Patient must have a family history of coronary heart disease in one or more first degree relatives before the age of 45 years; OR</p> <p>Patient must have heterozygous familial hypercholesterolaemia; OR</p> <p>Patient must have homozygous familial hypercholesterolaemia; OR</p> <p>Patient must have a level of absolute risk of a cardiovascular event greater than 15% over 5 years as calculated using the Australian Absolute Cardiovascular Disease Risk Calculator (National Vascular Disease Prevention Alliance), as in force on 1 April 2018.</p> <p>Inadequate control with a statin is defined as a LDL cholesterol concentration in excess of current target lipid levels for primary and secondary prevention after at least 3 months of treatment at a maximum tolerated dose of a statin.</p> <p>The dose and duration of statin treatment and the cholesterol concentration which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated.</p> <p>The cholesterol concentration which shows inadequate control must be no more than 2 months old when ezetimibe is initiated.</p> <p>Microalbuminuria is defined as urinary albumin excretion rate of greater than 20mcg/min or urinary albumin to creatinine ratio of greater than 2.5 for males, or greater than 3.5 for females.</p> |  |
|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

**[475] Schedule 4, Part 1, entry for Ezetimibe with simvastatin [Circumstances Code: C14056]**

- (a) omit from the column headed "Circumstances Code": **C14056** substitute: **C14269**
- (b) omit from the column headed "Purposes Code": **P14056** substitute: **P14269**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14056** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14269**

**[476] Schedule 4, Part 1, entry for Ezetimibe with simvastatin [Circumstances Code: C14057]**

- (a) omit from the column headed "Circumstances Code": **C14057** substitute: **C14284**
- (b) omit from the column headed "Purposes Code": **P14057** substitute: **P14284**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14057** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14284**

**[477] Schedule 4, Part 1, entry for Febuxostat [Circumstances Code: C14121]**

- (a) omit from the column headed "Circumstances Code": **C14121** substitute: **C14313**
- (b) omit from the column headed "Purposes Code": **P14121** substitute: **P14313**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14121** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14313**

- [478] **Schedule 4, Part 1, entry for Felodipine**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [479] **Schedule 4, Part 1, entry for Fenofibrate [Purposes Code: C14141]**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [480] **Schedule 4, Part 1, entry for Fluvastatin [Purposes Code: C14141]**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [481] **Schedule 4, Part 1, entry for Furosemide**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [482] **Schedule 4, Part 1, entry for Gemfibrozil**  
insert in numerical order after existing text:

|  |  |        |  |                                                                                                                                     |  |
|--|--|--------|--|-------------------------------------------------------------------------------------------------------------------------------------|--|
|  |  | P14238 |  | The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |  |
|--|--|--------|--|-------------------------------------------------------------------------------------------------------------------------------------|--|

- [483] **Schedule 4, Part 1, entry for Glyceryl trinitrate**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [484] **Schedule 4, Part 1, omit entry for Hydralazine**
- [485] **Schedule 4, Part 1, entry for Hydrochlorothiazide**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [486] **Schedule 4, Part 1, entry for Hydrochlorothiazide with amiloride**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [487] **Schedule 4, Part 1, entry for Indapamide**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [488] **Schedule 4, Part 1, entry for Irbesartan**  
omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

---

**[489] Schedule 4, Part 1, entry for Irbesartan with hydrochlorothiazide [Circumstances Code: C14061]**

(a) omit from the column headed "Circumstances Code": **C14061** substitute: **C14255**

(b) omit from the column headed "Purposes Code": **P14061** substitute: **P14255**

**[490] Schedule 4, Part 1, entry for Isosorbide dinitrate**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

**[491] Schedule 4, Part 1, entry for Isosorbide mononitrate**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

**[492] Schedule 4, Part 1, omit entry for Labetalol**

**[493] Schedule 4, Part 1, entry for Lercanidipine**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

**[494] Schedule 4, Part 1, entry for Lercanidipine with enalapril [Circumstances Code: C14049]**

(a) omit from the column headed "Circumstances Code": **C14049** substitute: **C14245**

(b) omit from the column headed "Purposes Code": **P14049** substitute: **P14245**

**[495] Schedule 4, Part 1, entry for Lisinopril**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

**[496] Schedule 4, Part 1, entry for Mesalazine**

omit:

|  |        |        |  |                                                                                                                                                           |  |
|--|--------|--------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|  | C14023 | P14023 |  | Ulcerative colitis<br>The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |  |
|--|--------|--------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--|

**[497] Schedule 4, Part 1, entry for Mesalazine [Circumstances Code: C14024]**

(a) omit from the column headed "Circumstances Code": **C14024** substitute: **C14229**

(b) omit from the column headed "Purposes Code": **P14024** substitute: **P14229**

---

**[498] Schedule 4, Part 1, entry for Mesalazine [Circumstances Code: C14120]**

- (a) omit from the column headed "Circumstances Code": **C14120** substitute: **C14260**  
(b) omit from the column headed "Purposes Code": **P14120** substitute: **P14260**

**[499] Schedule 4, Part 1, entry for Methyldopa**

- (a) omit from the column headed "Purposes Code" for the Circumstances Code "C13887": **P13887**  
(b) omit:

|  |        |        |  |                                                                                                                                     |  |
|--|--------|--------|--|-------------------------------------------------------------------------------------------------------------------------------------|--|
|  | C14141 | P14141 |  | The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |  |
|--|--------|--------|--|-------------------------------------------------------------------------------------------------------------------------------------|--|

**[500] Schedule 4, Part 1, entry for Metoprolol**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

**[501] Schedule 4, Part 1, entry for Metoprolol succinate [Circumstances Code: C14033]**

- (a) omit from the column headed "Circumstances Code": **C14033** substitute: **C14251**  
(b) omit from the column headed "Purposes Code": **P14033** substitute: **P14251**

**[502] Schedule 4, Part 1, entry for Moxonidine [Circumstances Code: C14037]**

- (a) omit from the column headed "Circumstances Code": **C14037** substitute: **C14289**  
(b) omit from the column headed "Purposes Code": **P14037** substitute: **P14289**

**[503] Schedule 4, Part 1, entry for Nebivolol [Circumstances Code: C14033]**

- (a) omit from the column headed "Circumstances Code": **C14033** substitute: **C14251**  
(b) omit from the column headed "Purposes Code": **P14033** substitute: **P14251**

**[504] Schedule 4, Part 1, entry for Nicorandil**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

**[505] Schedule 4, Part 1, entry for Nifedipine**

omit from the column headed "Purposes Code": **P14141** substitute: **P14238**

- 
- [506] **Schedule 4, Part 1, entry for Olmesartan**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [507] **Schedule 4, Part 1, entry for Olmesartan with amlodipine [Circumstances Code: C14043]**  
(a) *omit from the column headed "Circumstances Code": C14043* *substitute: C14257*  
(b) *omit from the column headed "Purposes Code": P14043* *substitute: P14257*
- [508] **Schedule 4, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide [Circumstances Code: C14062]**  
(a) *omit from the column headed "Circumstances Code": C14062* *substitute: C14272*  
(b) *omit from the column headed "Purposes Code": P14062* *substitute: P14272*
- [509] **Schedule 4, Part 1, entry for Olmesartan with hydrochlorothiazide [Circumstances Code: C14061]**  
(a) *omit from the column headed "Circumstances Code": C14061* *substitute: C14255*  
(b) *omit from the column headed "Purposes Code": P14061* *substitute: P14255*
- [510] **Schedule 4, Part 1, entry for Pancreatic extract [Circumstances Code: C14141]**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [511] **Schedule 4, Part 1, entry for Penicillamine**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [512] **Schedule 4, Part 1, entry for Perindopril**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [513] **Schedule 4, Part 1, entry for Perindopril with amlodipine [Circumstances Code: C14049]**  
(a) *omit from the column headed "Circumstances Code": C14049* *substitute: C14245*  
(b) *omit from the column headed "Purposes Code": P14049* *substitute: P14245*
- [514] **Schedule 4, Part 1, entry for Perindopril with amlodipine [Circumstances Code: C14068]**  
(a) *omit from the column headed "Circumstances Code": C14068* *substitute: C14246*  
(b) *omit from the column headed "Purposes Code": P14068* *substitute: P14246*
-

- 
- [515] **Schedule 4, Part 1, entry for Perindopril with indapamide [Circumstances Code: C14098]**  
(a) *omit from the column headed "Circumstances Code": C14098* *substitute: C14267*  
(b) *omit from the column headed "Purposes Code": P14098* *substitute: P14267*
- [516] **Schedule 4, Part 1, entry for Perindopril with indapamide [Purposes Code: C14141]**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [517] **Schedule 4, Part 1, entry for Potassium chloride**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [518] **Schedule 4, Part 1, entry for Potassium chloride with potassium bicarbonate**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [519] **Schedule 4, Part 1, entry for Pravastatin [Purposes Code: C14141]**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [520] **Schedule 4, Part 1, entry for Prazosin**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [521] **Schedule 4, Part 1, omit entry for Probenecid**
- [522] **Schedule 4, Part 1, entry for Propranolol**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
- [523] **Schedule 4, Part 1, omit entry for Quinapril**
- [524] **Schedule 4, Part 1, entry for Raloxifene [Circumstances Code: C14101]**  
(a) *omit from the column headed "Circumstances Code": C14101* *substitute: C14274*  
(b) *omit from the column headed "Purposes Code": P14101* *substitute: P14274*  
(c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": Compliance with Authority Required procedures - Streamlined Authority Code 14101* *substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14274*
- [525] **Schedule 4, Part 1, entry for Ramipril**  
*omit from the column headed "Purposes Code": P14141* *substitute: P14238*
-

- 
- [526] **Schedule 4, Part 1, entry for Ramipril with felodipine [Circumstances Code: C14049]**  
(a) omit from the column headed "Circumstances Code": **C14049** substitute: **C14245**  
(b) omit from the column headed "Purposes Code": **P14049** substitute: **P14245**
- [527] **Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14027]**  
(a) omit from the column headed "Circumstances Code": **C14027** substitute: **C14263**  
(b) omit from the column headed "Purposes Code": **P14027** substitute: **P14263**
- [528] **Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14028]**  
(a) omit from the column headed "Circumstances Code": **C14028** substitute: **C14235**  
(b) omit from the column headed "Purposes Code": **P14028** substitute: **P14235**
- [529] **Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14089]**  
(a) omit from the column headed "Circumstances Code": **C14089** substitute: **C14234**  
(b) omit from the column headed "Purposes Code": **P14089** substitute: **P14234**
- [530] **Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14059]**  
(a) omit from the column headed "Circumstances Code": **C14059** substitute: **C14301**  
(b) omit from the column headed "Purposes Code": **P14059** substitute: **P14301**  
(c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14059** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14301**
- [531] **Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14075]**  
(a) omit from the column headed "Circumstances Code": **C14075** substitute: **C14298**  
(b) omit from the column headed "Purposes Code": **P14075** substitute: **P14298**  
(c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14075** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14298**
- [532] **Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14095]**  
(a) omit from the column headed "Circumstances Code": **C14095** substitute: **C14264**  
(b) omit from the column headed "Purposes Code": **P14095** substitute: **P14264**
-

- (c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: **Compliance with Authority Required procedures - Streamlined Authority Code 14095** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14264**

**[533] Schedule 4, Part 1, entry for Rivaroxaban**

omit:

|        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                  |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| C14116 | P14116 | <p>Chronic stable atherosclerotic disease</p> <p>Initial treatment</p> <p>The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND</p> <p>The treatment must be in combination with aspirin, but not with any other anti-platelet therapy; AND</p> <p>Patient must have a diagnosis of coronary artery disease in addition to at least one of the following risk factors: (i) diagnosed heart failure (left ventricular ejection fraction of at least 30% but less than 50%) (ii) diagnosed kidney disease classified by an eGFR in the range of 15-60 mL/min (iii) diabetes mellitus combined with at least one of the following: (a) age at least 60 years (b) concomitant microalbuminuria (c) Aboriginal/Torres Strait Islander descent; OR</p> <p>Patient must have a diagnosis of peripheral artery disease in addition to at least one of the following risk factors: (i) concomitant coronary artery disease (ii) diagnosed heart failure (left ventricular ejection fraction of at least 30% but less than 50%) (iii) diagnosed kidney disease classified by an eGFR in the range of 15-60 mL/min (iv) diabetes mellitus combined with at least one of the following: (a) age at least 60 years (b) concomitant microalbuminuria (c) Aboriginal/Torres Strait Islander descent; AND</p> <p>Patient must have at least one of the following if coronary artery disease is present: (i) a previous multi-vessel coronary revascularisation procedure (ii) significant stenosis in at least 2 coronary arteries (iii) a previous single vessel coronary revascularisation procedure with significant stenosis in more than 1 coronary artery; OR</p> <p>Patient must have at least one of the following if peripheral arterial disease is present: (i) a previous peripheral/carotid artery revascularisation intervention (ii) intermittent claudication with an ankle-brachial index less than 0.9 (iii) asymptomatic carotid artery stenosis greater than 50%; AND</p> <p>The condition must be diagnosed by at least one of: (i) invasive (selective) angiography (ii) non-invasive imaging (i.e. CT scan, ultrasound) (iii) ankle-brachial index measurement in the case of peripheral arterial disease with intermittent claudication; AND</p> <p>Patient must have clinical findings/observations by the treating physician that exclude each of the following: (i) high risk of bleeding (ii) prior stroke within one month of treatment initiation (iii) prior haemorrhagic / lacunar stroke (iv) severe heart failure with a known ejection fraction less than 30% (v) New York Heart Association class III to IV heart failure symptoms (i.e. symptoms corresponding to moderate to severe limitation on physical activity, whereby any of fatigue/palpitations/dyspnoea occur upon zero to minimal activity) (vi) an estimated glomerular filtration rate less than 15 mL/minute (vii) a requirement for dual antiplatelet therapy (viii) a requirement for non-acetylsalicylic acid antiplatelet therapy (ix) a requirement for a higher dose of oral anticoagulant therapy.</p> <p>Must be treated by a specialist physician; OR</p> <p>Must be treated by a physician who has consulted a specialist physician.</p> | Compliance with Authority Required procedures - Streamlined Authority Code 14116 |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|

**[534] Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14139]**

- (a) omit from the column headed “Circumstances Code”: **C14139** substitute: **C14300**

- 
- (b) *omit from the column headed "Purposes Code":* **P14139** *substitute:* **P14300**
- (c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)":* **Compliance with Authority Required procedures - Streamlined Authority Code 14139** *substitute:* **Compliance with Authority Required procedures - Streamlined Authority Code 14300**
- [535] **Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14140]**
- (a) *omit from the column headed "Circumstances Code":* **C14140** *substitute:* **C14318**
- (b) *omit from the column headed "Purposes Code":* **P14140** *substitute:* **P14318**
- (c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)":* **Compliance with Authority Required procedures - Streamlined Authority Code 14140** *substitute:* **Compliance with Authority Required procedures - Streamlined Authority Code 14318**
- [536] **Schedule 4, Part 1, entry for Rosuvastatin [Purposes Code: C14141]**
- omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [537] **Schedule 4, Part 1, entry for Sacubitril with valsartan [Circumstances Code: C14051]**
- (a) *omit from the column headed "Circumstances Code":* **C14051** *substitute:* **C14254**
- (b) *omit from the column headed "Purposes Code":* **P14051** *substitute:* **P14254**
- (c) *omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)":* **Compliance with Authority Required procedures - Streamlined Authority Code 14051** *substitute:* **Compliance with Authority Required procedures - Streamlined Authority Code 14254**
- [538] **Schedule 4, Part 1, entry for Simvastatin [Purposes Code: C14141]**
- omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [539] **Schedule 4, Part 1, entry for Spironolactone**
- omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [540] **Schedule 4, Part 1, entry for Sulfasalazine [Purposes Code: C14141]**
- omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [541] **Schedule 4, Part 1, entry for Telmisartan**
- omit from the column headed "Purposes Code":* **P14141** *substitute:* **P14238**
- [542] **Schedule 4, Part 1, entry for Telmisartan with amlodipine [Circumstances Code: C14043]**
- (a) *omit from the column headed "Circumstances Code":* **C14043** *substitute:* **C14257**
-

- 
- (b) omit from the column headed "Purposes Code": **P14043** substitute: **P14257**
- [543] **Schedule 4, Part 1, entry for Telmisartan with hydrochlorothiazide [Circumstances Code: C14061]**
- (a) omit from the column headed "Circumstances Code": **C14061** substitute: **C14255**
- (b) omit from the column headed "Purposes Code": **P14061** substitute: **P14255**
- [544] **Schedule 4, Part 1, entry for Thiamine [Circumstances Code: C14020]**
- (a) omit from the column headed "Circumstances Code": **C14020** substitute: **C14319**
- (b) omit from the column headed "Purposes Code": **P14020** substitute: **P14319**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14020** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14319**
- [545] **Schedule 4, Part 1, entry for Ticagrelor [Circumstances Code: C14076]**
- (a) omit from the column headed "Circumstances Code": **C14076** substitute: **C14240**
- (b) omit from the column headed "Purposes Code": **P14076** substitute: **P14240**
- (c) omit from the column headed "Authority Requirements (part of Circumstances; or Conditions)": **Compliance with Authority Required procedures - Streamlined Authority Code 14076** substitute: **Compliance with Authority Required procedures - Streamlined Authority Code 14240**
- [546] **Schedule 4, Part 1, entry for Trandolapril**
- omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [547] **Schedule 4, Part 1, entry for Trandolapril with verapamil [Circumstances Code: C14119]**
- (a) omit from the column headed "Circumstances Code": **C14119** substitute: **C14244**
- (b) omit from the column headed "Purposes Code": **P14119** substitute: **P14244**
- [548] **Schedule 4, Part 1, entry for Valsartan**
- omit from the column headed "Purposes Code": **P14141** substitute: **P14238**
- [549] **Schedule 4, Part 1, entry for Valsartan with hydrochlorothiazide [Circumstances Code: C14061]**
- (a) omit from the column headed "Circumstances Code": **C14061** substitute: **C14255**
- (b) omit from the column headed "Purposes Code": **P14061** substitute: **P14255**
-

---

**[550] Schedule 4, Part 1, entry for Valsartan with hydrochlorothiazide [Circumstances Code: C14108]**

**(a)** *omit from the column headed "Circumstances Code": C14108* *substitute: C14311*

**(b)** *omit from the column headed "Purposes Code": P14108* *substitute: P14311*

**[551] Schedule 4, Part 1, entry for Verapamil**

*omit from the column headed "Purposes Code": P14141* *substitute: P14238*